Review

Brown Seaweed Food Supplementation: Effects on Allergy and Inflammation and Its Consequences

Simone E. M. Olsthoorn1,2, Xi Wang1,3, Berend Tillema4, Tim Vanmierlo5,6,*, Stefan Kraan7,8,*, Pieter J. M. Leenen2,†, and Monique T. Mulder1,*,†

Citation: Olsthoorn, S.E.M.; Wang, X.; Tillema, B.; Vanmierlo, T.; Kraan, S.; Leenen, P.J.M.; Mulder, M.T. Brown Seaweed Food Supplementation: Effects on Allergy and Inflammation and Its Consequences. Nutrients 2021, 13, 2613. https://doi.org/10.3390/nu13082613

Abstract: Multiple health benefits have been ascribed to brown seaweeds that are used traditionally as dietary component mostly in Asia. This systematic review summarizes information on the impact of brown seaweeds or components on inflammation, and inflammation-related pathologies, such as allergies, diabetes mellitus and obesity. We focus on oral supplementation thus intending the use of brown seaweeds as food additives. Despite the great diversity of experimental systems in which distinct species and compounds were tested for their effects on inflammation and immunity, a remarkably homogeneous picture arises. The predominant effects of consumption of brown seaweeds or compounds can be classified into three categories: (1) inhibition of reactive oxygen species, known to be important drivers of inflammation; (2) regulation, i.e., in most cases inhibition of proinflammatory NF-κB signaling; (3) modulation of adaptive immune responses, in particular by interfering with T-helper cell polarization. Over the last decades, several inflammation-related diseases have increased substantially. These include allergies and autoimmunity diseases as well as morbidities associated with lifestyle and aging. In this light, further development of brown seaweeds and seaweed compounds as functional foods and nutriceuticals might contribute to combat these challenges.

Keywords: seaweed; allergy; inflammation; oral

1. Introduction

Brown algae are one of three types of algae, i.e., brown algae (Phaeophyta), red algae (Rhodophyta) and green algae (Chlorophyta) classified based on their color and major photosynthetic pigments. Brown algae contain chlorophyll a, chlorophyll c and fucoxanthin, red algae contain chlorophyll a, chlorophyll d and phycoerythrin, while green algae contain chlorophyll a, chlorophyll b and xanthophylls. Due to the different abiotic and biotic factors in the marine environment and their distinct evolutionary origin seaweeds are a rich source of unique compounds of which several have demonstrated health benefits. Bioactive compounds of interest found in brown seaweeds include polysaccharides (e.g., alginate, fucoidan), proteins (e.g., phycobiliproteins), polyphenols (e.g., chlorotannins), carotenoids (e.g., fucoxanthin), phytosterols (fucosterol) and n-3 long-chain polyunsaturated fatty acids.
Nutrients 2021, 13, x FOR PEER REVIEW 2 of 55

(e.g., eicosapentaenoic acid) [1]. They have been reported to have beneficial effects in various diseases, including metabolic diseases, diabetes mellitus, cardiovascular disease, cancer and neurodegenerative diseases.

We structure this review according to the distinct compounds in brown seaweed that have been applied, and therefore distinguish effects of whole seaweeds or crude extracts (described in Section 3), polysaccharides such as fucoidan and alginate (Section 4), compounds with ring-shaped structures such as phytosterols (e.g., fucosterol) and (poly)phenols (e.g., phloroglucinol and phlorotannins) (Section 5) and carotenoids, in particular fucoxanthin, fucoxanthinol and meroterpenoids (Section 6).

For each of these compounds we discuss the demonstrated effects on different phases of the inflammatory response (schematically depicted in Figure 1). We describe (i) studies that investigate the brown seaweed (compound) effects on steady state immune parameters that influence subsequent responses to inflammatory challenges. Then, in view of the focus of this special issue on allergic disease, we separately discuss (ii) studies aimed at identifying the effects of intake of brown seaweed or -components on allergies and models thereof. As next steps (iii) and (iv), we distinguish brown seaweed effects on different phases in other acute inflammatory responses, with their characteristic read-outs as indicated in Table 1. Briefly, here we distinguish the first, immediate response (iii) typified by reactive oxygen radical production and release of early mediators such as IL-1, TNF and arachidonic acid metabolites. Then, we consider (iv) the seaweed effects on the second inflammation phase characterized by enhanced production of above-mentioned cytokines as well as secondary cytokines, such as IL-10, chemokines and other mediators, and infiltration of leukocytes in tissue. Finally, we discuss (v) the effects of seaweed intake on chronic inflammation, which is mostly low-grade, and their sequels. These include insulin-, leptin- or glucocorticoid resistance, which are related to the induction of diabetes, obesity and hampered down-regulation of inflammation, respectively. Furthermore, malignant transformation may be another consequence of chronic exposure to inflammatory conditions.

Figure 1. Schematic representation of brown seaweed and its constituents and of the phases in the immune response (Phase 0: steady state, allergy, Phase 1–2: acute inflammatory response and Phase 3: chronic inflammatory response) addressed in this review.
Table 1. Phases of the inflammatory response with characteristic features \(^{(1)}\).

| Phase      | Description                                      | Characteristic Read-Outs                                                                 |
|------------|--------------------------------------------------|----------------------------------------------------------------------------------------|
| 0 steady state | homeostatic condition                           | - growth, organ weight, etc.                                                            |
|            |                                                  | - leukocyte numbers and subset composition                                             |
|            |                                                  | - steady state activities, e.g., phagocytosis                                           |
| 1 short-term | initiation of inflammation as response to triggering by damage- or infection-related molecules | - mast cell and basophil degranulation                                                  |
|            |                                                  | - neuronal activation (e.g., scratching)                                                |
|            |                                                  | - reactive oxygen species (ROS)                                                        |
|            |                                                  | - pro-inflammatory arachidonic acid (AA) metabolites (e.g., PGE\(_2\))                  |
|            |                                                  | - phospholipase (PLA\(_2\)), cyclo-oxygenase (COX-2/PTGS2) and lipoxygenase (LOX/ALOX) activity |
|            |                                                  | - early pro-inflammatory cytokines (IL-1, TNF, IL-6 \(^{(2)}\))                        |
| 2 short-term | amplification and regulation of inflammation; initiation of adaptive immunity | - additional pro- and anti-inflammatory cytokines (e.g., IL-12, IL-10, IL-2)             |
|            |                                                  | - soluble forms of cellular R (e.g., sCD25, sCD163)                                    |
|            |                                                  | - chemokines (e.g., CXCL8, CCL2)                                                       |
|            |                                                  | - induction of iNOS and nitric oxide (NO) production                                    |
|            |                                                  | - anti-inflammatory AA metabolites (e.g., LXA4)                                        |
|            |                                                  | - endothelial activation                                                               |
|            |                                                  | - edema                                                                               |
|            |                                                  | - leukocyte mobilization and tissue infiltration                                       |
|            |                                                  | - acute phase proteins (e.g., CRP)                                                     |
|            |                                                  | - HPA-axis activation (cortisol or corticosterone)                                     |
|            |                                                  | - lymphocyte proliferation                                                             |
|            |                                                  | - microbial infection parameters                                                       |
|            |                                                  | - clearance and repair in short-term                                                  |
| 3 short- or long-term | consequences of severe or chronic inflammation | - clearance and repair in long-term                                                   |
|            |                                                  | - glucose, insulin resistance, diabetes                                               |
|            |                                                  | - adipokines, leptin resistance, obesity                                               |
|            |                                                  | - glucocorticoid resistance, stress, hampered down-regulation of inflammation          |
|            |                                                  | - inflammation-induced malignancy                                                     |

\(^{(1)}\) See Box 1 for a brief introduction on inflammation. \(^{(2)}\) In the inflammatory response, IL-6 is produced in a second wave, as it has to be expressed de novo, while initial TNF and IL-1\(\beta\) release only requires processing (i.e., membrane cut or enzymatic cleavage and secretion, resp.). Yet, IL-6 is frequently measured together with IL-1\(\beta\) and TNF. Therefore, IL-6 is classified in the first phase. In itself, it is an inducer of mediators of the second phase, in particular acute phase proteins.

Challenges to generating a comprehensible overview are the multifaceted aspects of allergy and inflammation, besides the large variety of brown seaweed species and preparations, as well as the different host species in which seaweed administration has been tested. Furthermore, this divergency bears a risk of overstretching conclusions based on limited findings. With these caveats in mind, we attempt to describe the commonalities between different studies, or discuss specific findings that deserve attention for future development. Detailed findings from the individual publications have been summarized in tables, linked to the compound categories mentioned above.
Inflammation is the response of tissues to any trigger significantly disturbing homeostatic conditions. These triggers can be manifold, and vary from infection or trauma, to metabolic challenges. The response is initiated by recognition of damage- or danger-related molecules (so-called DAMPs) that become exposed and are sensed by parenchymal tissue cells and resident innate immune cells, in particular macrophages and mast cells. Activation of these cells (Phase 1) stimulates a cascade of events, within the first seconds to minutes, involving local release of ready-made mediators such as histamine, inflammatory arachidonic acid products such as PGE\(_2\), and stored cytokines. Oxygen radicals (reactive oxygen species; ROS), produced by NADPH-oxidase complex assembled upon cellular activation and by mitochondria, further amplify activation of resident cells. In addition to their essential role in redox signaling, ROS are important as microbicidal molecules and as inducers of oxidative damage. Secreted first wave mediators alarm neighboring cells and stimulate local vascular cell activation, causing upregulation of adhesion molecules on the endothelial cell surface, and vasodilation. This enables plasma fluid, including bioactive proteins, to penetrate the tissue. Subsequently, activated resident cells produce inflammatory cytokines and chemokines by de novo gene transcription (Phase 2). Inflammatory signaling pathways involving NF-κB and AP-1, triggered by the receptor-DAMP interaction, are essential in this process. The released mediators amplify the inflammatory response and enable the recruitment of leukocytes from the circulation. Based on the profile of released chemokines, neutrophils are the most numerous attracted cells in the initial response. In addition, expression of inducible nitric oxide synthase (iNOS) is stimulated by bacterial products and pro-inflammatory cytokines, in particular IFN-γ. iNOS generates nitric oxide (NO), which is an important inflammatory mediator as microbicidal product of especially activated macrophages, and as an autocrine and paracrine signaling molecule. In this second phase of inflammation, also anti-inflammatory mediators are produced, which include arachidonic products such as lipoxins and resolvins, and cytokines such as IL-10. Dependent on the strength of the inflammatory trigger, systemic responses may occur, including activation of the hypothalamus-pituitary-adrenal (HPA) axis, leading to cortisol or corticosterone release. The first systemic cytokine wave initiates the production of so-called acute phase proteins such as C-reactive protein (CRP) from the liver, which occurs from approximately 24 h after the initial trigger. An adaptive immune response is initiated as DAMPs and -related antigens are transported to draining lymph nodes via lymph and migrating antigen-presenting cells. This leads to proliferation of antigen-specific B- and T-lymphocytes that eventually leave the lymph nodes and become effective in the periphery from approximately 4 days after initiation. Dependent on the nature and severity of the initial trigger, and ability to annihilate it, repair processes are initiated after a few days. If the trigger remains, such as in case of adverse metabolic conditions or persistent infection, inflammation may become chronic. Long-term exposure to adverse conditions thus may lead for instance to resistance to regulating hormones, such as insulin or cortisol. Allergic responses are inflammatory responses triggered by pre-existing antibodies or primed T-lymphocytes specific for harmless molecules from the environment. Best known are the responses caused by activation of mast cells evoked by IgE antibodies specific for innocuous antigens such as house dust mite or pollen. Other antibody subclasses with adverse specificities, for instance against certain drugs, also can cause clinical responses. Finally, T-lymphocytes with unfavorable specificities may cause so-called delayed-type hypersensitivity responses. The delay is explained by the necessity of T-lymphocytes to migrate to the site of antigen exposure and presentation, and to become activated locally. In essence, allergic responses follow the phases as outlined for the inflammatory response in general.

### 2. Approach to Systematic Search

The aim of this systematic review is to investigate the effect of brown seaweed components as a dietary supplement on inflammation with extra focus on allergies.

#### 2.1. Databases and Search Strategy

We performed two searches, in May and in November 2020. Several electronic databases were used to include studies: Embase via Embase.com (1971–Present), Medline ALL via Ovid (1946–Present), Web of Science Core Collection via Web of Knowledge (1975–Present), Cochrane Central Register of Controlled Trials via Wiley (1992–Present) and Google Scholar. References were filtered for duplicates in Endnote. The systematic search was executed by Elise Krabbendam, Biomedical Information Specialist at the Medical Library of Erasmus MC. The exact search terms are shown in the Supplementary Materials, where also a detailed flow chart of paper selection is shown. First, at least two review authors independently assessed title and abstract of the articles based on inclusion and exclusion criteria mentioned below. This was carried out using Endnote X9 software, based on reviewing methods described by Bramer et al. 2017 [2]. Secondly, after independent assessment of the articles, references selected by both review authors were included in a preliminary database. For final full text inclusion all references were combined and assessed by all review authors to assure eligibility and to extract important information to be included in the tables. References were divided by seaweed component among...
all review authors and based on full text selected to be included or excluded from the systematic review. Third, some relevant articles were included that were not retrieved in the systematic search, primarily because searchable parts of the articles did not contain reference to terms related to inflammation.

2.2. Eligibility Criteria

For this systematic review we only included articles written in English exclusively. Review articles were excluded from the search. The aim of the first search was to include papers addressing the effect of brown seaweed as nutritional supplement on leucocytes and how this contributes to the inflammatory process. This resulted in a total of 906 references after deduplication. For extra focus on allergy and atopy the search was expanded, resulting in a final total of 1035 references after deduplication. Papers on components of brown seaweed or whole extracts were included, but only when orally administered to human or animals. Exclusion criteria for this systematic review were seaweeds other than brown species or no oral administered. Furthermore, articles mentioning fucoidan as control inhibitor/blocker for selectins or scavenger receptor exclusively, were also excluded.

3. Whole Seaweed or Crude Extract Supplementation

3.1. Whole Seaweed or Crude Extract: Effects in Steady State

Table A1 summarizes the main findings of oral supplementation of whole seaweeds or crude extracts on inflammation-related parameters. Safety aspects of seaweed consumption are important to consider. Potential overload with iodine or heavy metals are major long-term risks when unprocessed edible seaweeds are ingested [1]. Short-term monitoring after administration of single doses of crude extracts in rodents showed no effects of toxicity up to 5000 mg/kg in mice (Sargassum micracanthum [3]; Cystoseira compressa (Esper) [4]), or showed LD50 values of 1000–2000 mg/kg (Fucus vesiculosus [5]). Considering a dosage of 200 mg/kg/day is routinely applied for regular use, it may be argued that the safe dosage range might be limited. However, specific toxicity may be highly batch-dependent and related to toxic contaminants rather than seaweed content.

A widely studied facet of seaweed supplementation is its high anti-oxidant activity, and related to this, anti-inflammatory activity. Human studies in this direction are scarce, however. Consumption of 4.8 g dried Sargassum muticum per day for a period of 4 weeks by healthy volunteers stimulated an increased total anti-oxidant status in serum, correlated to decreased concentrations of oxidized LDL [6]. In contrast to general assumptions, Baldrick et al. observed no significant changes in oxidative or inflammatory parameters after oral consumption of Ascophyllum nodosum extract by individuals with overweight or obesity (100 mg/day, 8 weeks) [7]. An interesting aspect of the latter study is that individuals differed notably (up to >4000×) in the total amount of seaweed polyphenol metabolites present in urine. It is tempting to speculate this might be attributed to differences in microbiota composition between individuals. In a study in goat, where Ascophyllum nodosum extract was added (2%) to feed, an increased anti-oxidant status was shown [8]. Similarly, 4-week treatment of rats with Fucus vesiculosus extract stimulated increased serum paraoxonase and superoxide dismutase activities, thus leading to an increased anti-oxidant status [5].

Effects of seaweed supplementation on blood cell counts are variable; studies in human or other mammals showed limited effects [6,8], but increased counts were observed when chicken and fish were fed Laminaria japonica or Sargassum oligocystum, respectively [9,10]. Such addition to animal feed is not only associated with increased growth and feed conversion ratios in chicken and fish, but also enhanced status of innate and adaptive immune defenses and immune responsiveness and survival after infectious challenge [11–13].

3.2. Whole Seaweed or Crude Extract: Effects on Allergy

Importantly, oral brown seaweed supplementation shows consistent beneficial effects in different models of allergy (Table A1). Eisenia (=Ecklonia) arborea powder intake by Brown Norway rats, orally sensitized to ovalbumin, leads to decreased serum IgE and histamine
levels and decreased IL-4 and IL-10 production in lymphoid organs, while IFN-γ synthesis is increased. This indicates a favorable change in Th1/Th2 balance towards the former [14].

Mouse models using 2,4-dinitrophenol (DNP) or 2,4-dinitrochlorobenzene (DNCB) sensibilization and challenge are much used in this field, and similarly show positive effects of brown seaweed intake. *Sargassum horneri* extract has anti-allergic activity by suppressing degranulation of mast cells and basophils. This reduces nasal rubbing [15] or clinical signs of atopic dermatitis, as well as inflammatory cytokine levels and leukocyte skin infiltrates [16] in these allergy models. Similarly, application of extracts from *Costaria costata* [17] and *Laminaria japonica* [18] reduce severity of allergic dermatitis and stimulate healing, possibly by decreasing inflammatory pathways in keratinocytes.

### 3.3. Whole Seaweed or Crude Extract: Effects in Acute and Chronic Inflammation

Without prior sensitization, irritant application on murine skin also causes signs of acute inflammation associated with local mast cell degranulation and increased vascular permeability. Feeding rats with *Laminaria japonica* extract decreases paw swelling and leukocyte infiltration induced by carrageenan application, likely by inhibiting NF-κB activation causing decreased inflammatory mediator production [19] (Table A1). Similarly, oral or topical administration of *Sargassum fusiforme* extract significantly reduces ear swelling by inhibiting mast cell degranulation and enzymes involved in production of inflammatory arachidonic acid mediators [20].

The challenge of experimental animals or isolated cells with lipopolysaccharide (LPS) is a common model of acute inflammation, mimicking the response to bacterial infection. A 5-week treatment of rats with *Eisenia (=Ecklonia) bicyclis* extract mediated a reduced inflammatory activation of peritoneal macrophages upon in vitro LPS stimulation through inhibition of NF-κB activity [21]. This was associated with reduced iNOS expression and nitric oxide (NO) production. In marked contrast, a similar study in mice showed that 3-week oral treatment with *Sargassum fusiforme* (also called *Hizikia*) extract slightly potentiated the production of IL-1β, IL-6 and TNF-α by isolated peritoneal macrophages stimulated in vitro with LPS [22]. In accordance with an inflammation-regulating effect, 4-day oral application of *Sargassum serratifolium* extract in mice caused significantly reduced production of TNF-α, IL-1β and IL-6 upon in vivo LPS challenge [23]. This confirmed the in vitro findings of direct inhibition of NF-κB activation and nuclear translocation by seaweed components.

Investigation of seaweed treatment on LPS responses in other than murine species generally corroborated an inflammation-inhibiting effect. Challenge of zebrafish embryos with LPS or H₂O₂ showed reduced reactive oxygen species (ROS) production and associated cell death when treated simultaneously with *Sargassum polycystum* or *Chnoospora minima* extract [24].

 Adding *Sargassum latifolium* to sheep feed caused a reduced inflammatory response to LPS challenge and increased blood anti-oxidant defense capacity [25]. This seaweed treatment also mediated a reduced inflammatory response to heat stress challenge in these sheep [26]. The latter study confirms earlier work in lamb, showing reduction of heat stress-related effects on leukocyte oxidative and phagocytic function by *Ascophyllum nodosum* extract administration [27].

Furthermore, in mouse models of inflammatory disease, seaweed supplementation has shown beneficial effects. In dextran sulfate sodium-induced chronic colitis, application of *Turbinaria ornata* extract causes decreased disease activity as indicated by colon length, histomorphological index and myeloperoxidase activity [28]. This was accompanied by increased expression of regulatory T-cell-associated FoxP3 and anti-inflammatory IL-10. Similarly, *Laminaria japonica* extract caused a significant diminution of colitis signs in this model, and simultaneous application of bacterial probiotics showed synergistic beneficial effects on histological score and decreased levels of some proinflammatory cytokines [29]. In a mouse model of arthritis induced by bovine type II collagen immunization, oral
supplementation with *Sargassum muticum* extract significantly decreased the arthritis and edema scores as well as TNF, IL-6 and IFN-γ levels [30].

In one of the scarce human studies, Cooper et al. found that individuals with active Herpes infection showed increased healing rates with *Undaria pinnatifida* consumption, while latent Herpes carriers did not experience viral reactivation [31]. Investigating the mechanisms, the authors found the extract strongly inhibited Herpes virus infectivity in vitro, and stimulated human T cell mitogenesis, thus potentiating adaptive immune responses.

A study using a phylogenetically more distinct organism, kuruma shrimp, indicated that oral supplementation with *Laminaria japonica* significantly increased survival upon White Spot Syndrome virus infection [32]. This was accompanied by enhancement of chemotaxis as well as other defense mechanisms by hemolymph leukocytes (hemocytes), including superoxide production and antioxidative phenoloxidase activity upon appropriate stimulation.

### 3.4. Whole Seaweed or Crude Extract: Late Consequences of Inflammation and Sequels

Acute or chronic inflammatory conditions influence local and systemic tissue responses, and thus seaweed supplementation also affects peripheral tissue function in inflammation (Table A1). In a rat model of ligature-induced periodontitis, *Sargassum fusiforme* (*Hizikia*) application reduced alveolar bone loss, related to decreased osteoclast and increased osteoblast gene expression in vitro [33]. Furthermore, in a model of autoimmune thyroiditis, a traditional Chinese medicine combination of 10 different herbs, including *Sargassum fusiforme*, mediated a decrease in autoimmune thyroiditis and anti-thyroid autoantibody formation [34]. Omission of *Sargassum fusiforme* in this model significantly diminished the protective effect.

In recent years, the link between adipose tissue metabolic dysregulation and inflammation has been recognized increasingly [35]. Several studies investigated metabolic effects of seaweed application, in particular *Undaria pinnatifida*, in murine models of obesity and type 2 diabetes induced by a high-fat diet [36–38]. Seaweed was in some studies combined with other nutraceuticals. In general, the obesity phenotype did not change, while improvement of glucose regulation was only observed by Oh et al. (2016) [36], but not in the other two studies. Other aspects, however, showed beneficial effects of seaweed supplementation, such as microbiome composition, MCP-1 induction [38], systolic blood pressure and non-esterified fatty acid levels [37] or presence of clusters of necrotic adipocytes surrounded by macrophages in adipose tissue (so-called crown-like structures) [36].

A pathological condition strongly related to obesity is the polycystic ovary syndrome (PCOS). In a rat model of PCOS, application of *Ecklonia cava* extract mediated a decrease in vaginal leukocyte infiltration, and restored hormonal levels and irregular ovarian cycles [39]. However, it did not inhibit the weight gain associated with PCOS induction.

### 4. Brown Seaweed Polysaccharide Supplementation

Among polysaccharides present in brown seaweed fucoidan has received most attention as a constituent with diverse bioactive effects. Furthermore, bioactivity has been demonstrated of the polysaccharides laminarin, a beta-glucan polysaccharide and alginate, a linear acidic soluble dietary polysaccharide.

Fucoidans are a group of polysaccharides (fucans) primarily composed of sulphated L-fucose with less than 10% of other monosaccharides. They are widely found in the cell walls of brown seaweeds, but not in other algae or higher terrestrial plants [40]. The major function of fucoidans in cell walls is mechanical support and protection against desiccation during air-exposure of the seaweed at low tide. The amount of fucoidan in brown seaweeds is variable; 8–20% of dry weight with the highest content of about 20% being detected in *Fucus vesiculosus* [41,42].

A number of health-improving effects have been ascribed to fucoidans [40,41,43]. Biological activities of fucoidans, such as antioxidant and anti-coagulant capacity, are affected
by their molecular weight and sulphated ester content, both the number of sulphate groups, determining the negative charge of the molecule and the position of the sulphate groups on the sugar residues [40,44]. The biological activity of fucoidan is also affected by the glucuronic acid and fucose content. The molecular weight of fucoidan ranges from for example from 50 to 80 KDa in Undaria pinnatifida and Fucus vesiculosus, respectively, to 1920 kDa in Cladosiphon species [45], with multiple sizes being present in certain species. Low molecular weight (LMW) fucoidan is produced by enzymatic digestion or acid hydrolysis of naturally occurring high molecular weight (HWM) fucoidan. Application of different molecular species of fucoidan obtained by different methods of purification and treatments such as hydrolysis complicates interpretation of results.

4.1. Brown Seaweed Polysaccharide Effects in Steady State

Fucoidan is absorbed in limited amounts in the gastrointestinal tract after oral intake [46,47]. In Japanese populations where brown seaweed is part of daily diet, systemic fucoidan uptake was shown by its presence in serum and urine [48]. Protective effects of fucoidan on the intestinal epithelial barrier function were observed in vitro. Fucoidan protected the tight junctions from oxidative injury and upregulated the expression of claudin-1 [49]. Table A2 summarizes the effects of fucoidan on different aspects of inflammation.

Fucoidan is not toxic, but high dosages can induce increased bleeding time. In rats no toxicity as observed after oral administration of a single dose of Ascophyllum nodosum fucoidan of 2000 mg/kg [50] or 300 mg/kg/day Laminaria japonica fucoidan for 6 months [51]. However, application of a daily dose of 2500 mg/kg for 6 months resulted in increased bleeding time. The application of fucoidan in food has been approved for human consumption up to 250 mg/day by the European Food Safety Authority, EFSA [1].

4.2. Effects of Polysaccharides from Brown Seaweed in Allergy, Acute Inflammation and in the Modulation of Immune Responses

Both pro- and anti-inflammatory effects of fucoidan have been reported. In macrophages fucoidan treatment induced NF-κB nuclear translocation, followed by iNOS and COX-2 transcription, inducing the secretion of the pro-inflammatory cytokines IFN-γ, TNF-α and IL-1β and of inflammatory mediators NO and PGE2 [52]. However, pre-treatment of macrophages and lymphocytes with fucoidan prior to stimulation with LPS or other pro-inflammatory stimuli was found to blunt the pro-inflammatory reaction or induces an anti-inflammatory effect, resulting in inhibition of NF-κB translocation and in lower levels of pro-inflammatory mediator production [53–56].

Below an elaboration on anti-allergy effects and enhanced immune effects in production animals and innate and adaptive immune system modulation studies in mice is described.

4.2.1. Anti-Allergic Effects of Brown Seaweed-Derived Polysaccharides

Overall, oral supplementation of brown seaweed polysaccharides was reported to inhibit allergic responses via multiple mechanisms. The polysaccharides were shown to be an effective agent antagonizing IgE production as examined in different ovalbumin (OVA)-sensitized mouse models [57,58], but also an allergy-specific mechanism of oral fucoidan supplementation has been found in its capacity to induce galectin-9 production from intestinal cells [59,60]. Galectin-9, belonging to a soluble lectin family, recognizes β-galactoside and prevents IgE binding to mast cells, consequently inhibiting mast cell degranulation. Accordingly, fucoidan from Saccharina japonica (400 µg for 4 days) was found to increase circulating galectin-9 [59]. After OVA-immunization the allergic symptoms in sensitized mice were reduced by fucoidan (60 µg/mouse/d for 17 days) via inducing galectin-9 production from colonic epithelial cells [60].

In several OVA-immunized mouse models, oral administration of fucoidan or a polysaccharide fraction was shown to have anti-allergy activity. Application of a polysaccharide fraction from Laminaria japonica (50 mg/kg/day for 2 weeks) in a mouse model of
asthma significantly decreased the numbers of eosinophils in the bronchoalveolar fluid and alleviated lung inflammation compared to the non-treated control mice [58]. It also reduced serum IgE concentrations and decreased the concentrations of IL-13 and TGF-β1 in bronchoalveolar fluid and expression in lung, while increasing expression of IL-12. Similarly, Laminaria japonica fucoidan ingestion (200, 600, 1000 mg/kg for 6 weeks) decreased OVA-specific IgE in mice [61]. Fucoidan from Undaria pinnatifida (400 mg/kg for 7 days) inhibited particulate matter-induced exacerbation of allergic asthma [57]. Specifically, fucoidan treatment significantly attenuated lipid peroxidation, infiltration of inflammatory cells and Th2-related IL-4 concentrations. Furthermore, fucoidan suppressed mast cell activation, degranulation and IgE synthesis as well as mucus hypersecretion and goblet cell hyperplasia. This also is reflected in immunoglobulin isotypes produced as Cladosiphon-fucoidan dose-dependently (up to 1025 mg/kg body weight for 8 weeks) increased systemic IgM, IgG and IgA levels, while decreasing IgE and IL-4 significantly [62].

The observed changes are suggestive of a shift from Th2 to Th1 induced by orally ingested fucoidan. Enhanced IL-12 and IFN-γ production by ingestion of Tetragenococcus halophilus KK221, a probiotic known for its anti-allergic properties, was even further increased by combined ingestion of the probiotic and LMW fucoidan isolated from Undaria pinnatifida in OVA-immunized mice. The results indicated an extra shift towards Th1.

Furthermore, alginate was found to improve (food) allergy outcomes in an OVA-sensitized mouse model [63]. Ingestion of alginate (2 mg) extracted from Laminaria japonica one day before oral application of ovalbumin improved integrity of intestinal epithelial villi and inhibited mast cell degranulation in the jejunum. Serum levels of IgE, histamine and IL-4 were significantly lower, while IFN-γ was markedly increased. Furthermore, Tregs in spleen were increased, while OVA-induced differentiation of Th0 cells into Th2 cells was inhibited [63].

Overall, brown seaweed-derived polysaccharides generally appear to modulate the Th1/Th2 balance and mast cell degranulation in favor of an anti-allergic effect. This shows that fucoidan is potentially an effective therapeutic agent for type I allergic diseases.

4.2.2. Effects of Brown Seaweed Polysaccharides on Innate and Adaptive Immune System (Production Animals)

In search for alternatives for antibiotics in production animals, brown seaweed polysaccharides and especially fucoidan, have appeared as promising functional feed additives. Fucoidan and laminarin were found to improve the immune response of pregnant sows and piglets prior to or while suckling [64], and after weaning [65].

Dietary supplementation of sows in the final part of gestation with Laminaria spp. extract increased IgG and IgA in sow colostrum by 19% to 25% [64]. Consequently, also a 10% increase in piglet serum IgG was observed. This suggests an important effect of maternal diet on the immune status of piglets. Dietary supplementation with an extract of Ascophyllum nodosum and Fucus in sows (30 g/day from the 85th day of gestation until weaning) resulted in an increased population of CD4+CD8+ T cells in the thymus, spleen, mesenteric node, liver and in peripheral blood as compared to the control group [66]. Piglets from laminarin-fed sows (1.0 g/d from day 107 of gestation until weaning) showed down-regulation of IL-6 mRNA expression in the colon at weaning and of IL-8 in the ileum on day 8 post weaning compared with those from the non-laminarin-fed sows [67].

Weaning of piglets is a stressful event for piglets and is often associated with pro-inflammatory immune effects in the piglets’ gastro-intestinal tract. Addition of laminarin to weaning piglets’ diets resulted in lower expression of pro-inflammatory cytokines IL-1β, IL-6 and IL-17 in colonic mucosa [65]. Even though these positive effects were observed in piglets, laminarin did not result in any detectable benefits in Friesian bull calves [68].

In Salmonella-challenged broiler chickens, addition of 0.2% alginic oligosaccharides to the regular diet inhibited Salmonella enteritis colonization, possibly by increasing colonic anti-Salmonella IgA levels [69]. In unchallenged broiler chickens, supplementation of 0.2% alginic oligosaccharides showed dramatic immunostimulatory activity by inducing interferon-γ, IL-10 and IL-1β mRNA expression in cecal tonsils. Interestingly, the robust
mucosal immune response in the absence of a challenge was related to a decline in body weight, as compared to the control group.

In aquaculture, several studies pointed at improved innate immune markers upon fucoidan and laminarin supplementation in shrimp and fish [70–76]. In addition, higher survival rates during bacterial challenges were observed in the supplemented animals, as compared with those fed a regular diet.

Taken together, enhancing the innate and adaptive immune system by oral ingestion of seaweed-derived polysaccharides and oligosaccharides is a promising solution for improving animal health, reducing infection incidence and reducing the need for antibiotics use.

4.2.3. Effects of Brown Seaweed Polysaccharides on Innate and Adaptive Immune System (Mouse Models)

Polysaccharides obtained from brown seaweed may support various aspects of the immune system in both immunocompetent and immunosuppressed states. For instance, oral ingestion of a polysaccharide extract from *Kjellmaniella crassifolia* (2 weeks) by C57BL/6 mice, resulted in enhanced IFN-γ, IL-12, IL-6 and IgA secretions by spleen cell cultures upon concanavalin-A stimulation [77]. Orally administered LMW fucoidan (200–1000 mg/kg for 6 weeks) from *Laminaria japonica* to BALB/c mice stimulated the innate immune system by increasing natural killer (NK) cell activity and peritoneal macrophage phagocytic activity [61]. LMW fucoidan also increased IL-2, IL-4 and IFN-γ secretion by splenocytes and IgG and IgA concentrations in serum, while it decreased OVA-specific IgE. In bacterial antigen-stimulated immune responses, the IgM and IgG concentrations in serum were significantly higher in the LMW fucoidan group than in the control group. In addition, an LMW fucoidan-enriched extract from *Okinawa mozuku* orally administered (up to 1025.0 mg/kg for 6 weeks) to BALB/c mice resulted in enhanced splenocyte proliferation and secreted IL-2 levels, as well as in increased macrophage phagocytic activity, and serum IgM, IgG and IgA, while splenocyte-secreted IL-4 and IL-5 were decreased, and also serum IgE was decreased significantly [62]. Interestingly, HMW fucoidan (50 g/kg) but not LMW and IMW fucoidan, increased the relative number of cytotoxic T-cells in spleens of Balb/c mice [78]. These immune-potentiating effects appear to be effective in infection as complete elimination of liver and spleen parasite burden was achieved by fucoidan (200 mg/kg, 3 times weekly, for 6-weeks) in a mouse model of *Leishmania donovani* infection [79]. This curative effect was associated with switching of T cell differentiation from Th2 to Th1 mode.

In addition to its capacity to enhance the innate and adaptive immune system, oral fucoaid is an interesting candidate for antiviral therapies related to its intrinsic capacity as a competitive binding agent for envelope viruses, thus preventing cellular entrance [80]. Oral ingestion of fucoidan improves the outcome in virus-infection mouse models with respect to viral load [81], serum antibody levels and overall survival [82,83] in immunocompetent and immune-suppressed mice. Furthermore, fucoidan extracted from *Undaria pinnatifida* protected both immunocompetent and immunosuppressed mice from infection with HSV-1 as indicated by the improved survival rate and lesion scores [82]. In immunocompetent mice fucoidan enhanced activity of CTL and increased circulating anti-HSV antibodies in HSV-1-infected mice.

In an immunosuppressed state, selective augmentation of NK activity was observed upon oral treatment with *Undaria* fucoidan, but this induced no significant change in NK activity in immunocompetent mice where a normal level of NK activity was maintained. Fucoidan extracted from *Undaria pinnatifida* showed also beneficial effects during influenza virus infection in immunocompetent an immunosuppressed mice [83]. Fucoidan administration (7 days prior to virus inoculation until 7 days after inoculation (2 × 5 mg/day)) resulted in significant increase in neutralizing antibody titers in bronchoalveolar lavage fluids in both healthy mice and mice with suppressed immunity as compared with placebo groups.
Furthermore, in the defense against tumors fucoidans enhance innate and adaptive immune responses. Different fucoidans were found to increase immune reactions in various tumor models, leading to comparable or even better results than standard chemotherapy exclusively [84–87]. Consumption of fucoidan isolated from Undaria pinnatifida (1% of the diet for a period of 10 days) showed tumor inhibition in an A20 leukemia mouse model, related to enhanced Th1 and NK cell activity [84]. Oral intake of polysaccharides from Sargassum fusiforme (100 and 200 mg/kg for 28 days) significantly inhibited the growth of A549 lung adenocarcinoma in mice, but also remarkably promoted IL-1 and TNF-α production from peritoneal macrophages, increased serum TNF-α levels and splenocyte proliferation [87]. Oral administration of fucoidan extracted from Cladosiphon okamuranus (5 g/kg/day for 28 days) also inhibited tumor growth and increased survival time in a colon 26 tumor-bearing mouse model. In the spleens of these mice, an increased population of NK cells was observed. Furthermore, in an experiment applying the same fucoidan to MyD88 knockout mice, a model for investigating TLR4 signaling pathways, it was found that the observed anti-tumor effects are related to gut immunity [85]. Furthermore, polysaccharide extract from Sargassum fusiforme (400 mg/kg for 28 days) exerted anti-tumor and immunomodulatory activities in nasopharyngeal carcinoma [86] and hepatic carcinoma tumor-bearing mice [88]. In a xenograft tumor model orally administered fucoidan from Fucus vesiculosus (150 mg/kg body weight daily for 2 weeks) increased cytolytic activity of NK cells and significantly delayed tumor growth [89]. Furthermore, in a rat model for experimental mammary carcinogenesis administration of fucoidan (400 mg/kg/day for 4 months) showed protective and immunomodulatory effects [90]. Tumor growth in Sarcoma 180 (S-180)-bearing mice was delayed by ingestion of fucoidan from Cladosiphon okamuranus, which stimulated NO production by macrophages via NF-κB-dependent signaling pathways [52]. Oral intake of ascosphyllan, a sulphated polysaccharide obtained from Ascophyllum nodosum, (50 and 500 mg/kg), also delayed tumor growth. Interestingly, oral ingestion significantly increased serum IL-12 and TNF-α levels and mediated better overall outcome compared to intraperitoneal application in S-180 mice, where immune markers did not change [91].

Seaweed polysaccharides can also function as immune-stimulating adjuvant in immunosuppressed states during chemotherapy. Oral intake of polysaccharide extract from Sargassum fusiforme (200 mg/kg for 6 days) was identified as a potent immune-enhancing agent in immunosuppressed mice [92]. Oral administration of fucoidan (150 mg/kg for 14 days) resulted in enhanced recovery of all T cell populations (CD3+, CD4+, CD8+) and of the proliferative capacity of splenocytes in immunosuppressed mice [93]. Furthermore, laminarin administration (500–1000 mg/kg/day for 10 days) induced IL-12 and IFN-γ in immunosuppressed mice [94]. Taken together, oral intake of brown seaweed polysaccharides is shown to be an effective immune enhancer in a wide variety of mouse models.

4.2.4. Anti-Inflammatory Effects of Fucoidan in Animal Models and Clinical Trials

Fucoidans extracted from different seaweed species and molecular sizes showed anti-inflammatory effect in a wide range of acute and chronic inflammation models in mice.

In an arachidonic acid-induced ear inflammation model sulphated polysaccharide extracted from Sargassum hemiphyllum decreased ear swelling and erythema [95]. The polysaccharides decreased the local levels of myeloperoxidase, nitric oxide, IL-1β, IL-6 and TNF-α in a dose-dependent manner (20–80 mg/kg body weight for 5 consecutive days). Histological examination revealed that the polysaccharides reduced the area of neutrophilic infiltration in inflamed ears. Similarly, oral ingestion of fucoidan extracted from Undaria pinnatifida (0.5 mg for 20 days) inhibited the inflammatory reaction in a mouse model where LPS was injected buccally [55]. In the same set up, but now using bacterial infection, fucoidan reduced inflammation but did not lead to clearance of the bacterial infection, nor to prevention of infection-related bone loss. In a carrageenan-induced air pouch inflammation model, a preparation of fucoidan (54 mg/kg for 7 days) inhibited in-
flamatory markers and showed reduced attraction of inflammatory cells as demonstrated by histology [96]. Pretreatment with orally administered fucoidan (20 mg/kg for 2 weeks) reduced mucosal lining inflammation and prevented elevation of serum IL-6 levels, while levels of serum IL-10 increased in an aspirin-induced mucosal ulcer model in mice [97]. Accordingly, Cladosiphon fucoidan (chow containing 0.05% w/w) ingestion beneficially affected murine dextran sulphate sodium (DSS)-induced colitis [98]. The lamina propria of inflamed colon showed reduced amounts of IL-6 and IFN-γ, and an increase in IL-10 and TGF-β upon fucoidan treatment. Murine DSS-induced colitis significantly improved upon treatment with fucoidan (10 mg/day for 1 week) [99]. Treatment with a fucoidan-polyphenol complex showed even better results as it reduced IL-12, TNF-α and IL-6 in colitis tissue and ameliorated colitis-related visible body markers, such as weight loss and blood in stool. In contrast, when this complex was injected intraperitoneally, it was unable to reduce disease severity and even deteriorated some colitis markers. In mice, colonic inflammation and microbiota dysbiosis induced by antibiotics was alleviated by administration of fucoidan extracted from Ascophyllum nodosum (400 mg/kg for 28 days) [100]. Fucoidan prevented colon shortening and colon tissue damage, and it improved abundance of beneficial microbes while decreasing harmful microbes. In a model with chemically induced colorectal cancer, ingestion of Fucus vesiculosus fucoidan was shown to protect against tumorigenesis and to reduce colorectal inflammation and dysbiosis [101].

The bioactivity of fucoidan is related to its molecular weight. LMW and HMW fucoidan from Undaria pinnatifida were tested in a murine model of collagen-induced arthritis [102]. LMW fucoidan protected against tissue degeneration, while the same dose of HMW fucoidan worsened it. In accordence, LMWF reduced the severity of arthritis and the levels of Th1-dependent collagen-specific IgG2a, while HMWF enhanced the severity arthritis and the levels of collagen-specific antibodies.

Furthermore, in different acute inflammation models in zebrafish embryos, strikingly similar anti-inflammatory effects were noticed [53,54,56,103]. Administration of fucoidan (25–100 µg/mL) one hour prior to LPS treatment improved survival of zebrafish embryos and diminished inflammatory markers.

In support of an inflammation-regulating effect of fucoidan, oral administration of Laminaria japonica fucoidan (50–200 mg/kg) protected against myocardial ischemia–reperfusion injury in rats in a dose-dependent manner [104]. Furthermore, oral ingestion of enzymatically hydrolyzed fucoidan extracted from Sargassum hemiphyllum (200 mg/kg/day for 14 days) decreased radiation-induced pneumonitis and lung fibrosis by reducing inflammatory cytokine expression in lung tissues [105]. In both models decreased accumulation of neutrophils and macrophages was observed.

In a mouse model of chronic infection with Schistosoma japonicum oral ingestion of Fucus vesiculosus fucoidan (500 mg/kg per 2 days for 40 days) significantly reduced the hepatic granuloma size and fibrosis response [106]. Lower levels of pro-inflammatory cytokines were observed in the livers of fucoidan-treated infected mice. Infiltration of Treg cells and levels of IL-10 and TGF-β were significantly enhanced in both the livers and spleens from fucoidan-treated mice. Another study aimed to explore the effects of fucoidan from Fucus vesiculosus on concanavalin A (ConA)-induced acute liver injury in mice. Pretreatment with fucoidan (10–50 mg/kg for 2 weeks) protected liver function indicated by ALT, AST and histopathological changes by suppressing inflammatory cytokines, TNF-α and IFN-γ [107]. The results demonstrated that fucoidan alleviated ConA-induced acute liver injury via the inhibition of intrinsic and extrinsic apoptosis mediated by the TRADD/TRAF2 and JAK2/STAT1 pathways which were activated by TNF-α and IFN-γ.

Fucoidan from Fucus vesiculosus (300–600 mg/kg) was shown to be able to delay the onset and incidence of autoimmune diabetes in non-obese diabetic mice via regulating DC/Treg-induced immune tolerance via induction of IL-10 and TGF-β, while reducing the levels of IL-6 and IFN-γ [108]. In the pancreas TLR4 expression and the downstream molecules were downregulated while pancreatic internal environment was maintained in the fucoidan-treated groups.
In a clinical trial in patients with chronic hepatitis B infection, oral ingestion of a commercial oligo-fucoidan preparation (550 mg twice a day for 48 weeks) was shown to have hepatoprotective effects related to serum concentrations of vitamin D, which is known to have immunoregulatory activity [109]. A clinical trial in healthy volunteers showed anti-inflammatory effects of a blend containing fucoidan from 3 different seaweeds. Daily oral ingestion of 1000 mg for 4 weeks was found to decrease serum IL-6 levels [110]. In advanced cancer patients a mixture of enzymatically digested and undigested fucoidan from Cladosiphon novae caledoniae (4 weeks of 4000 mg/day) was found to reduce several major proinflammatory cytokines, including IL-1β, IL-6 and TNF-α [111]. The analyses revealed that the responsiveness of IL-1β was inversely correlated with overall survival and was suggested as a possible prognostic factor for disease outcome in advanced cancer patients receiving fucoidan.

Taken together, brown seaweed polysaccharide ingestion is shown to be effective in antagonizing the effects of acute and chronic inflammation in both mouse models and clinical trials.

4.3. Fucoidan Ingestion and Atherosclerosis in Animal Models

Several studies have reported beneficial effects of fucoidan on outcome of atherosclerosis, a disease related to long-term inflammation of the arterial vessel wall.

ApoE-deficient mice are the most frequently used model for assessing atherosclerotic plaque development. In one study, sulphated polysaccharides from Laminaria japonica supplementation markedly reduced the thickness of the lipid-rich plaque, lipid peroxidation and foamy macrophage accumulation in the aorta via suppression of MAPKs and NF-κB signaling [112]. In line, Wang et al. found that Laminaria japonica fucoidan (50–100 mg/kg/day for 16 weeks) attenuated atherosclerosis by reducing inflammation and oxidative stress [113]. Furthermore, LMW fucoidan extracted from Laminaria japonica inhibited the formation of atherosclerotic plaques; and ameliorated the occurrence and development of atherosclerosis [114]. It decreased the production of inflammatory cytokines and prevented macrophages from developing into foam cells and diminished smooth muscle cells from migrating into the intimal layer of the aorta.

Furthermore, also in other models of atherosclerosis, fucoidan appears to have beneficial effects. In a rat allogenic aorta transplantation model ad libitum ingestion of fucoidan from Fucus vesiculosus mediated anti-atherosclerotic activity by inhibiting inflammation, suppressing ROS production and down-regulating LOX-1 expression in the vascular wall [115]. In a rat aorta transplantation model fucoidan (LMW) from Laminaria japonica (200 mg/kg/day for 35 days) decreased the number of macrophages in the vascular wall by blocking P-selectin activity thereby preventing the development of aortic aneurysms [116]. In the LDLR−/− mouse model of atherosclerosis Laminaria japonica fucoidan (50–100 mg/kg/day for 16 weeks) was shown to result in atherosclerosis attenuation by reducing inflammation and oxidative stress [113]. In conclusion, fucoidan appears to be promising in the battle against atherosclerosis by decreasing macrophage infiltration in the vascular wall, as well as by reducing inflammation and oxidative stress.

5. Phenolic Compounds and Phytosterols

5.1. Phytosterols

Phytosterols, including both sterols, stanols and oxysterols, such as fucosterol, saringosterol and 24-hydroperoxy-24-vinyl-cholesterol, are a group of functional lipid compounds. Compared to other bioactive molecules produced by brown algae, phytosterols exhibit various health-improving effects, especially neuroprotective and anti-inflammatory. Table A3 presents an overview of the significant inflammation-related outcomes in animal models after oral administration of phytosterols. Fucosterol, the most abundant sterol in brown seaweed, when administered in different animal models was found to induce a significant therapeutic effect on injury- or infection-related inflammation. Mo et al. [117] showed anti-inflammatory effects of fucosterol-pretreatment in Concanavalin A-treated mice as a model
for acute liver injury. After Concanavalin A-treatment, NF-κB p65 increased markedly and the expression of a nuclear receptor in its upstream pathway, PPARγ, decreased. Both NF-κB p65 and PPARγ are closely related to the release of inflammatory factors such as TNF-α, IL-6 and IL-1β. Fucosterol pretreatment down-regulated the inflammatory response and subsequently necrosis and apoptosis by inhibiting the NF-κB pathway and activating PPARγ.

Anti-inflammatory effects of fucosterol were demonstrated using regular Sargassum fusiforme extracts (NH) and enzyme-modified Sargassum fusiforme extracts (EH) [22]. Enzyme modification significantly increased the fucosterol concentration in the extract (EH) leading to better results in decreasing pro-inflammatory cytokines as compared to the NH pretreatment group. In addition, both NH and EH reduced the production of NO without inducing any cytotoxicity and even increased cell viability in cultured RAW264.7 macrophages at a concentration of 10 μg/mL or higher. Anti-inflammatory effects of fucosterol were also observed in DNCB-induced NC/Nga mice as a model for atopic dermatitis. Oral administration of fucosterol significantly reduced [22] the scratching behavior of the mice and suppressed the production of pro-inflammatory cytokines (TNF-α and IL-4), resulting in reduced circulating IgE levels.

Bogie et al. showed that 24(S)-Saringosterol, an oxyphtosterol present in Sargassum fusiforme, has anti-inflammatory effects likely via activation of liver X receptor (LXR)β in a mouse model of Alzheimer’s disease (AD) [118]. Sargassum fusiforme extract rich in 24(S)-Saringosterol activated LXRβ preferentially and to a lesser extent also LXRα. LXRβ plays a key role in the down-regulation of the expression of multiple inflammatory genes [119,120]. AD is characterized by an accumulation of extracellular amyloid-β (Aβ), intracellular neurofibrillary tangles, loss of synapses, neuroinflammation and by a gradual progression of memory loss. After 45 days of dietary supplementation with Sargassum fusiforme the formation of Aβ plaques which is related to cognitive decline, was found to be dramatically reduced (~80% reduction) in AD mice. The expression of the LXR-target gene APOE in the central nervous system was increased due to administration of Sargassum fusiforme lipid extract. Apolipoprotein (Apo)E increased the clearance of Aβ by microglial cells and suppressed the secretion of Aβ by neurons in vitro. Therefore, the anti-inflammatory effects of 24(S)-Saringosterol may be explained by activation of the LXR-ApoE axis [121].

Similar to 24(S)-Saringosterol-mediated LXRβ activation, fucosterol can activate both LXRα and LXRβ, regulating different aspects of inflammatory gene expression.

5.2. Polyphenols

Polyphenols are another class of bioactive compounds from brown seaweed that have attracted great interest in recent years due to their pharmaceutical and biomedical properties. Polyphenols are classified based on their structure. Phlorotannins, highly abundant in brown seaweeds, are polymerized phenolic compounds consisting of phloroglucinol monomer units. Phlorotannins identified in brown seaweed, include eckol, dieckol, phlorofucofuroeckol A. Numerous studies have demonstrated the potential of polyphenol classes as antioxidant, anti-inflammatory, antidiabetic, antitumor, antihypertensive, anti-allergic, hepato-protective and anti-cancer. Table A4 provides an overview of the reported inflammation-related outcomes after oral administration of polyphenols in different animal models and in clinical trials. (Phase 0, 1, 2 and 3).

5.2.1. Polyphenols: Effects in Steady State

The mechanisms underlying the anti-inflammatory effects of polyphenols are complex and are related to various stages of the inflammatory response that are sequential but overlapping. Disturbance of the steady state causes parenchymal tissue and immune cells to respond to injury or irritation through an innate cascade driving inflammation. Irfan et al. [122] demonstrated that phlorotannins strongly inhibit in vivo platelet aggregation in Sprague Dawley rats. In line with this in vitro, phlorotannins downregulated adenosine diphosphate-induced platelet activation (Ca-mobilization, fibrinogen binding, granule
release—mediated via decreased Src, PI3K, PLCγ2, MAPK signaling). A clinical trial with 80 overweight participants showed that phlorotannins modestly decrease DNA damage [7], although no significant difference was found in acute phase proteins, anti-oxidant status or in inflammatory cytokines.

5.2.2. Polyphenols: Effects on Allergy

NF-κB is one of the transcription factors that regulates eosinophilic inflammation and IgE-mediated hyperreactivity following allergic inflammation. Oral administration of polyphenols suppressed NF-κB pathway activation, and also inhibited inhibitor kappa B (IκB) that binds to NF-κB [123,124]. Polyphenols were found to alleviate particulate matter-induced airway inflammation in an allergic asthma mouse model [124]. Polyphenol treatment was found to decrease the inflammatory cell count in blood, including eosinophils, neutrophils, basophils. The level of epithelial cytokines, including IL-25, IL-33 and IL-8 also were reduced in the polyphenol-treated mice [124]. Han et al. [123] reported that pretreatment of BALB/c mice, as a model for passive cutaneous anaphylaxis, with Eckol inhibited the production of IL-4, IL-5, IL-6 and IL-13. Moreover, Eckol-treatment suppressed levels of β-hexosaminidase, secreted during the degranulation of mast cells. In addition, oral polyphenol administration was found to reduce the levels of FcεRI on the surface of IgE/bovine serum albumin (BSA)-stimulated mouse bone marrow-derived cultured mast cells (BMCMC). Cross-linking of FcεRI and allergen-specific IgE triggers allergic reactions that may be prevented by polyphenols. These results suggested that Eckol has anti-allergic potential. In a mouse ear-edema model both oral and local administration of phlorotannin, 1-21h prior to irritant application, strongly inhibited arachidonic acid (AA), 12-O-tetradecanoylphorbol-13-acetate (TPA) and immune-mediated (oxazolone (OXA))-induced ear swelling (30–80%) [125]. This suggests that the inhibitory effects of polyphenols are comparable to those of known anti-allergic agents. It was presumed that polyphenols play an anti-inflammatory effect by inhibiting mast cell degranulation, COX-2- and LOX-, and to lesser extent PLA2 activities.

5.2.3. Polyphenols: Effects in Acute and Chronic Inflammation

Inflammation is a beneficial host response for foreign invaders and necrotic tissue with phase 1 being the first, immediate response, typified by ROS production and release of early mediators such as IL-1, TNF-α and arachidonic acid pro-inflammatory metabolites. Once detected extracellularly, ingested microbes will lead to upregulation of TLRs a family of proteins involved in the initial phase of host defense against invading pathogens. TLR4 is the most common member in inflammation phases. Excessive TLR activation, however, disrupts the immune homeostasis by sustained production of pro-inflammatory cytokines and chemokines.

Polyphenols were demonstrated to be very well capable of suppressing the increase of TLRs, including TLR4 [124,126,127], TLR2 [124,127] and TLR7 [124]. TLRs as primary sensors of microbial products activate signaling pathways that lead to the induction of immune- and inflammatory genes, such as the NF-κB pathway. Polyphenol treatment also significantly decreased NF-κB and thereby the modulation of inflammation-related signaling cascades [123,124,126–131].

ROS are a crucial factor in the inflammatory response, playing multiple roles after tissue injury, including initiation of acute inflammation, clarifying infection and necrotic tissue and mediation of various intracellular signal transduction pathways. Anti-inflammatory effects of polyphenols via antioxidant activities were demonstrated by Kang et al. [132]. They found that serum ferric reducing antioxidant power (FRAP) significantly increased 30 min after polyphenol treatment in the Sprague Dawley rat-model but declined quickly thereafter. Polyphenols showed anti-inflammatory effects by reducing the expression of ROS [131,133–135]. Administration of the polyphenol-rich fraction of Ecklonia cava reduced ROS and NO generation in LPS-stimulated inflammation in zebrafish [133]. ROS can activate a variety of transcription factors leading to the differential expression of genes
involved in inflammatory pathways. On the other hand, excessive production of ROS can cause irreversible damage to DNA. Due to this dual effect, polyphenols often show a crucial effect in tumor models by upregulating ROS in tumor cells and at the same time downregulating ROS in healthy cells. Yang et al. [129] indicated that oral administration of phlorotannins to the SKOV3-bearing mouse model of ovarian cancer enhances cancer cell apoptosis via upregulation of the ROS pathway but protects against healthy kidney cell damage by downregulating ROS levels. Tissue damage leads to a rapid increase in ROS which stimulates PGE2 production via the activation of COX-2. Polyphenols exert anti-inflammatory effects not only by suppressing COX-2 [128,130,131,136], but also by reducing PGE2 production [130,131] which exacerbates inflammatory responses and immune diseases. The production of early inflammatory cytokines such as TNF-α, IL-6 and IL-1β, that is increased in phase 1, was significantly inhibited by oral administration of polyphenols in vivo, in different mouse, rat and zebrafish models [124,126–128,130,131,135,137–139], and also in vitro, in RAW264.7 macrophages [131,134]. Polyphenol treatment [128,138] decreased the expression of CCL2/MCP-1 and consequently may reduce the infiltration of macrophages and subsequently inflammation [126,128].

In phase 2, the regulation of inflammation is amplified via positive feedback and adaptive immunity is activated. Oral administration of polyphenols significantly affects macrophage infiltration and the balance of macrophages with an M1 or M2 phenotype. Oral administration of polyphenols decreased the expression of CD11b and CD80, markers for M1 macrophages [126,127,137,138]. The M2 type is identified by marker CD206, and can prominently expresses IL-10, a cytokine with potential anti-inflammatory effects and plays an important role in limiting the host immune response to pathogens. Polyphenol treatment was found to increase the expression of the M2 markers, CD206 [126,127,137,138] and IL-10 in acute liver injured mouse model and HFD with or without seaweed supplement mouse model [124,127,135,138]. Oral administration of polyphenols induced a decrease in the level of iNOS [130,131,134,138] and the levels of NO in both.

5.2.4. Polyphenols: Late Consequences of Inflammation and Sequels

Oral administration of polyphenols may be promising for the treatment of severe or chronic inflammation and its consequences (phase 3). Oral administration of polyphenols resulted in a reduction in food intake and in body weight [126–128,137,140], as well as in the storage of triglyceride (TG) and total cholesterol (TC) [128,137]. After oral administration of extracts rich in polyphenols, also the leptin/adiponectin ratio, an important marker for inflammation and obesity, decreased [128]. Choi et al. and Son et al. [127,137] showed that the production of receptor for advanced glycation end-products (RAGE), closely related to inflammation and visceral fat hypertrophy, and RAGE-RAGE ligand binding was reduced in obese individuals treated with polyphenols. In obesity-associated type 2 diabetes, low-grade chronic inflammation can lead to an increase of blood glucose levels and to insulin resistance. Polyphenol treatment improved insulin sensitivity [128] and suppressed the increase of blood glucose levels in high-fat diet-induced obese mice [140]. A novel derivative from phloroglucinol called Compound 21 significantly exerted protective effects on multiple sclerosis through promotion of remyelination and suppressing neuroinflammation in a cuprizone-induced mouse model for multiple sclerosis [141]. In another study these authors showed that Compound 21 reduced the population of Th1/Th17 cells and inhibited their infiltration into the CNS. These results indicated a potential neuroprotective effect of Compound 21 [142].

In conclusion, polyphenols have various therapeutic effects including anti-inflammatory, anti-obesity, anti-diabetic and antioxidant. Polyphenols may be a highly promising treatment strategy for diseases involving chronic low-grade inflammation, but further clinical studies are needed.
6. Fucoxanthin(ol) and Meroterpenoids

Fucoxanthin is a major marine carotenoid present in chloroplasts of brown seaweeds, and particularly seaweeds such as Undaria pinnatifida, Laminaria japonica and Sargassum honeri are rich in fucoxanthin [143]. Ingested fucoxanthin is metabolized to fucoxanthinol in the small intestine and then absorbed [144]. Therefore, fucoxanthinol has a higher bioavailability than fucoxanthin. Multiple potentially beneficial health effects have been ascribed to both fucoxanthin and fucoxanthinol; e.g., anti-oxidative, anti-inflammatory, anti-obesity, anti-diabetic and anti-carcinogenic properties [145,146]. Meroterpenoids are partially derived from a terpenoid pathway (mero- means partial). Tetraterpenoids, of which carotenoids are the most common representatives, belong to the terpenoids and consist of eight isoprene units [147]. Meroterpenes can be isolated from brown algae such as Sargassum serratifolium. The meroterpenoid-rich fraction from the ethanolic extract (MES) of this brown alga is known for its antioxidant and anti-inflammatory activities [148]. Table A5 presents an overview of the significant outcomes of studies investigating oral administration of fucoxanthin, fucoxanthinol or MES in animal models related to the inflammatory response.

6.1. Fucoxanthin(ol) and Meroterpenoids: Effects in Acute and Chronic Inflammation

Fucoxanthin is known for its antioxidant potential through its ability to scavenge radicals effectively and to enhance enzymatic antioxidant activity [149]. Enhanced activity of antioxidant enzymes superoxide dismutase (SOD), catalase (Cat) and glutathione peroxidase (GPx) was observed in plasma and testis of rats [150], mice [151] and hamsters [152] after treatment with fucoxanthin. Fucoxanthin reduced the increased production of ROS as a consequence of increased oxidative stress and reduced the increased malondialdehyde formation during lipid peroxidation, which in turn causes upregulation of pro-inflammatory cytokine production [153,154]. Malondialdehyde levels were reduced in plasma, sperm and/or testicular tissue of rats [150], mice [151,155] and hamsters [152] after fucoxanthin treatment. Additionally, a reduction of ROS, such as superoxide (O$_2^-$) and hydrogen peroxide (H$_2$O$_2$) was seen both in vivo and in vitro after oral administration of fucoxanthin [150–152,155].

Oral administration of fucoxanthin in different animal models decreased the expression of various pro-inflammatory mediators, including cytokines such as TNF-α, IL-6 and IL-1β. This was observed in white adipose tissue, plasma, testis and colonic tissue after stimulation with various inflammatory triggers [150,151,155,156]. Sugiura et al. demonstrated the anti-inflammatory and inhibitory effects of oral or percutaneous administration of fucoxanthin on mouse ear swelling induced by different irritants [157]. Fucoxanthin and fucoxanthinol were shown to inhibit the enzymatic activities of PLA$_2$ and COX-2, thus restraining the generation of pro-inflammatory arachidonic acid metabolites in these mice. These anti-inflammatory effects of fucoxanthin and fucoxanthinol were also confirmed in vitro using rat basophilic leukemia cells, which showed reduced mRNA expression of sPLA$_2$ and COX-2 upon treatment with both fucoxanthin and fucoxanthinol [157]. In addition, Tan et al. found that COX-2 and iNOS mRNA expression were downregulated in obese mice upon fucoxanthin administration [155]. Similarly, Maeda et al. demonstrated decreased expression of MCP-1 in white adipose tissue in mice with obesity-related inflammation upon treatment [145,156]. Since MCP-1 is a pro-inflammatory cytokine this suggests an anti-inflammatory effect of fucoxanthin on adipocytes. In mouse models of DSS-induced colitis and colitis-associated colon carcinoma, a reduction in total NO content and in NO release in colonic tissue was observed after oral administration of fucoxanthin [151]. Moreover, NO production was also reduced after treatment with fucoxanthin in cisplatin-induced testicular damage in hamsters [152]. Additionally, the meroterpenoid-rich fraction of an ethanolic extract from Sargassum serratifolium (MES) induced anti-inflammatory activities in high-cholesterol-fed mice. The mice demonstrated decreased serum levels of MCP-1 and keratinocyte chemoattractant, which are pro-inflammatory chemokines causing monocyte adhesion in vascular lesions. Furthermore, MES supplementation resulted in
reduction of ICAM-1, VCAM-1, MCP-1, COX-2 and MMP-9 expression in aortic tissue. These results indicated that MES prevented vascular inflammation in these mice [148]. Similarly, mice fed a high-fat diet supplemented with MES, compared to un-supplemented high-fat diet showed decreased expression of macrophage markers F4/80 and MCP-1, indicating a suppression of inflammation [158).

6.2. Fucoxanthin(ol) and Meroterpenoids: Late Consequences of Inflammation and Sequels

Related to the inflammation in adipose and other tissues, oral fucoxanthin supplementation was also shown to have effects counteracting obesity and obesity-related morbidity [159]. Administration of fucoxanthin to mice fed a high-fat diet reduced gain in body weight and in weight of white adipose tissue as compared to chow-fed control mice [155,156]. Furthermore, Maeda et al. demonstrated that mice fed a high-fat diet also receiving fucoxanthin displayed significantly lower plasma levels of LDL-cholesterol and leptin compared to mice that were fed a high-fat diet only, indicative of moderated metabolic dysregulation [156]. Additionally, the obesity-related reduction in expression of beta-3 adrenergic receptor (ADRB3), responsible for lipolysis and thermogenesis [160], appeared significantly restored in mice upon addition of fucoxanthin to their high fat diet [156]. Moreover, Tan et al. showed a decrease in myeloperoxidase (MPO) activity in mice with high-fat diet-induced obesity after oral fucoxanthin administration, which implies a reduction in polymorphonuclear cell infiltration [155]. In addition, MES supplementation suppressed body weight, TG, glucose and free fatty acid concentrations in plasma of high fat diet-fed mice. In addition, the lower HDL cholesterol levels increased to comparable levels as in the control group. Moreover, increased expression of UCP-1 and ADRB3 in subcutaneous tissues demonstrates that MES supplementation causes conversion of white to beige/brite adipocytes which resembles brown adipose tissue [158]. These results suggest anti-obesity effects and inhibition of lipogenesis by MES supplementation.

In line with improvement of metabolic functions induced by fucoxanthin supplementation, anti-diabetic effects of fucoxanthin have been observed [145,150,156]. Feeding a high fat-diet containing fucoxanthin resulted in decreased plasma insulin and blood glucose levels in mice, to levels similar as in mice fed a regular diet [156]. Moreover, mRNA levels of GLUT4, encoding the insulin-sensitive glucose transporter in adipose tissue and muscle, were restored to normal levels when the high fat diet was supplemented with fucoxanthin [156]. In the diabetic KK-Ay mouse model fucoxanthin consumption was found to decrease elevated plasma blood glucose concentrations [145]. It was also shown that glucose intolerance improved by fucoxanthin dietary addition [145]. More recently, Kong et al. found that treatment of diabetic rats with fucoxanthin significantly reduced levels of plasma glucose compared to diabetic rats without any treatment [150]. Insulin concentrations and homeostatic model assessment of insulin resistance (HOMA-IR) levels were significantly reduced in these rats. Finally, fucoxanthin supplementation inhibited the expression of the suppressor of cytokine singaling-3 (SOCS-3), involved in the induction of insulin resistance [150]. Together, these results indicate that fucoxanthin possesses anti-diabetic effects by suppressing inflammation and thereby improving insulin sensitivity.

7. Concluding Remarks

In this comprehensive systematic review, we aimed to provide an overview on the modulating role of intake of complete brown seaweed, its extracts or selected compounds on the modulation on different aspects of the inflammatory immune response. This includes the impacts of seaweed consumption on steady state immune parameters, effects on allergies, the innate and adaptive immune response and also on chronic, low-grade inflammation. Brown seaweeds constitute a group of approximately 2000 species containing several common but also unique bioactive molecules with immunomodulatory functions. We therefore distinguished the impact of four different categories of compounds, i.e., polysaccharides, (poly)phenols, phytosterols and carotenoids.
We identified three common denominators across the effects of brown seaweed and constituents thereof on inflammation (represented in Figure 2). Firstly, most purified compounds, despite their diverse chemical nature, appear to inhibit similar aspects of inflammation, in particular synthesis of reactive oxygen species. This common effect is rather puzzling. Yet, a caveat of some studies may be the use of compound concentrations beyond physiological levels. In addition, purification of the compounds used in the cited studies mostly left sufficient room for concentrations of contaminants that might contribute to, or even explain, the claimed effects. In our view, this calls for rigorous comparative research of the various compounds in an identical experimental setting. Nevertheless, the suppression of reactive oxygen species provides an interesting angle to study immunomodulatory effects of brown seaweed constituents.

Secondly, brown seaweeds interfere with the innate immune response on the level of TLR-induced NF-κB signaling. This route is actually linked with the previous one since oxygen radicals drive and amplify innate NF-κB-mediated activation. In conjunction, a plethora of in vitro and in vivo experiments support a suppression of IL-6, IL-1, iNOS and TNF-α upon treatment with brown seaweeds. Polyphenols, fucosterol, fucoxanthin and fucoidan all seem to be active in this. Yet, when fucoidan was applied in the pretreatment setting, it was also shown to potentiate the NF-κB axis to reduce susceptibility to infection via scavenger receptor A and TLR4 activation in an antibiotic-like fashion. These seemingly contradictory findings underscore the versatile properties of brown seaweed constituents in the modulation of the innate immune response. Therefore, interpretation should be performed with care when extrapolating in vitro findings to human applications. Nevertheless, most in vivo studies summarized in this review show unequivocal anti-inflammatory effects. The mechanistic background of brown seaweed health benefits probably goes beyond direct inhibition of inflammation. Multiple studies indicate that brown seaweed compounds interact with pathways and processes involved with energy sensing and sur-
vival, such as AKT/mTOR/AMPK and autophagy. Thus, brown seaweed compounds might also function as caloric restriction mimetics and thereby stimulate vitality.

Thirdly, the adaptive immune response displays an altered Th1/Th2 response in response to brown seaweed. Different constituents have been identified to skew the Th1/Th2 balance. Depending on the molecular weight of the fucoidan, different outcomes have been identified. Fucosterol has been shown to skew Th0 cells into Th2 cells in a model for allergy, whereas polyphenols suppress the Th1/Th17 response in an animal model for MS. The net effect of brown seaweed on Th1/Th2 skewing cannot be generalized and is largely dependent on the composition of the different constituents in the seaweed. On the level of allergy, Th2 suppression reduces IL-4 cytokine levels, decreased IgE production and suppressed mast cell activity.

Inflammation is a universal response of the body to damage, infection or otherwise disturbed homeostasis. For this review, we have restricted the search terms to those that are related to inflammation, allergy and immunity. The broad implication of the inflammatory response in the maintenance of bodily integrity, however, entails that several studies that focus on aspects only indirectly related to inflammation, were not included in the final result, whereas similar studies were, based on different choices by the respective authors for their specific wording. Nevertheless, we are confident that this review covers the main aspects of oral supplementation of brown seaweeds and their components on aspects of inflammation, allergy and immunity in a broad sense. More well-designed human studies applying individual seaweed constituents as well as whole seaweed (extracts) will provide more insight into the applicability of brown seaweed as immune-modulatory nutritional intervention strategies.

Supplementary Materials: The following are available online at https://www.mdpi.com/article/10.3390/nu13082613/s1, Supplementary Figure S1: Flowchart of systematic search and search strategies.

Author Contributions: Conceptualization, S.E.M.O., P.J.M.L. and M.T.M.; methodology, S.E.M.O., P.J.M.L. and M.T.M.; validation, S.E.M.O., X.W., B.T., P.J.M.L. and M.T.M.; investigation, S.E.M.O., X.W., B.T., S.K., P.J.M.L. and M.T.M.; data curation, S.E.M.O., B.T.; writing—original draft preparation, S.E.M.O., X.W., B.T., T.V., S.K., P.J.M.L. and M.T.M.; writing—review and editing, S.E.M.O., X.W., B.T., T.V., S.K., P.J.M.L. and M.T.M.; visualization, X.W., P.J.M.L., M.T.M.; supervision, P.J.M.L., M.T.M.; project administration, S.E.M.O., M.T.M.; funding acquisition, M.T.M. All authors have read and agreed to the published version of the manuscript.

Funding: This work was supported by Health Holland (HHINT Kickstarter #LSH17004), Alzheimer Nederland (WE.03-2018-06 AN) and NWO-TTW (#16437).

Acknowledgments: The authors wish to thank librarian Elise Krabbendam for her important contributions and support in the initial phases of the generation of this review.

Conflicts of Interest: The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results. S.E.M.O., X.W., T.V., P.J.M.L. and M.T.M. declare no conflicts of interest. S.K. and B.T. are professionally involved with seaweed farming and -products but have no commercial interests in the content of this review.
## Appendix A

**Table A1. Effects of oral supplementation of whole brown seaweeds or crude extracts on inflammation-related parameters.**

| Compound/Format                              | Effective Concentrations | Algal Source               | Experimental Model                  | Inflammatory Phase | Significant Findings                                                                 | Reference |
|----------------------------------------------|--------------------------|----------------------------|-------------------------------------|--------------------|--------------------------------------------------------------------------------------|-----------|
| EtOH extract                                 | 300–2000–5000 mg/kg; single dose | *Sargassum micracanthum*   | BALB/c mouse; toxicity; follow-up 2 weeks | steady state       | non-toxic up to 5000 mg/kg                                                           | [3]       |
| EtOH-H$_2$O extracts                         | single dose LD50 = 500–2000 mg/kg; oxidative stress reduction: 200 mg/kg/day, 4 weeks | *Fucus vesiculosus* | Swiss mouse; Sprague Dawley rat; toxicity: acute anti-oxidant activity: 4 weeks | steady state       | LD$_{50}$ acute toxic $> 750$ mg/kg; 4 week supplementation: ↓ 13% food intake in 4 week; 30–50% ↓ WBC but no change in differential counts; 20–25% ↑ in liver and kidney weight; ↑ PON-1 activity (protects against ox-LDL); ↑ SOD | [5]       |
| MeOH-, hexane- or chloroform-extract         | >2000 mg/kg, single dose | *Cystoseira compressa* (Esper) | male and female albino mouse; toxicity | steady state       | no lethality in oral testing (2000 mg/kg)                                             | [4]       |
| EtOH extract, polyphenol-rich ultrafiltrate  | 100 mg/day, 8 weeks      | *Ascophyllum nodosum*      | human, BMI ≥ 25                     | steady state       | marginal ↓ lymphocyte DNA damage in only obese; ↓ oxLDL (14%); correlated to ↑ total antioxidant status; ↓ fatigue; ↑ NK count = lymphocyte count; ↑ liver function (↓ AST, ALT) | [7]       |
| whole, dried                                 | 4.8 g/day, 4 weeks       | *Sargassum muticum*        | human                               | steady state       | ↓ NK count; ↓ lymphocyte count = fatigue; ↑ liver function (↓ AST, ALT)              | [6]       |
| Compound/Format | Effective Concentrations | Algal Source | Experimental Model | Inflammatory Phase 1 | Significant Findings 2 | Reference |
|-----------------|--------------------------|--------------|--------------------|----------------------|------------------------|-----------|
| commercial extract | 2% in feed, 3 weeks | *Ascophyllum nodosum* | Spanish and Boer × Spanish goat; stress by transport and feed withholding | steady state | =cortisol =WBC and subset counts, but ↓ Eosinophil =phagocytosis ↓ lipid peroxidation; ↓ SOD (strain diff.) ↑ glutathione peroxidase (10–15%) | [8] |
| commercial extract | 0.5% in feed; 41 weeks | *Ascophyllum nodosum* | Lohmann LSL-Lite and Lohmann Brown-Lite hens, heat stress | steady state | short-term ↓ feed intake; ↑ feed/egg efficiency strain-dependent ↑ production, ↑ feed efficiency, ↑ heat stress resistance, improved ALP, ALT, GGT liver parameters | [161] |
| seaweed powder + anti-bacterial peptides (cecropin) | 1–5% of basal diet | *Laminaria japonica* | Arbor Acres broiler chicks | steady state | synergistic effect of seaweed + cecropin: ↑ antibodies, ↑ lymphocytes, microbiota: ↑ *Lactobacillus*, ↓ *E.coli* ↑ feed conversion ratio | [9] |
| hot water extract | 100–500 mg/kg in feed, 12 weeks | *Sargassum oligocystum* (Panagiasianodon hypophthalamus) | fish, Pangasius | steady state | ↑ weight, daily growth rate, feed conversion ratio ↑ WBC, RBC, Hb, Hc, platelets | [10] |
| seaweed meal | 3–6–9% in feed, 6 weeks | *Sargassum ilicifolium* | fish, Asian sea bass (*Lates calcarifer*) | steady state | ↑ growth; ↑ pancreatic enzyme activities ↑ serum Ig; (alternative) complement pathway components, lysozyme ↑ Ig in skin mucus ↑ liver SOD, IL-1β mRNA | [11] |
| Compound/Format       | Effective Concentrations | Algal Source        | Experimental Model | Inflammatory Phase | Significant Findings                                                                 | Reference |
|-----------------------|--------------------------|---------------------|--------------------|--------------------|--------------------------------------------------------------------------------------|-----------|
| whole seaweed         | 10% in feed, 8 weeks     | *Sargassum ilicifolium* | fish, great sturgeon (*Huso huso*) | steady state       | ⬆ growth, ⬆ serum protein, lysozyme, IgM, respiratory burst, complement ⬆ Hb, RBC, WBC ⬆ TG, LDH, AST, ALT ⬇ blood cholesterol ⬆ survival upon *Yersinia ruckeri* infection (14 days infection) | [12]      |
| aqueous extract       | 400 mg/kg, 8 weeks       | *Sargassum angustifolium* | fish, rainbow trout (*Oncorhynchus mykiss*) | steady state       | ⬆ weight gain, ⬆ Hb, Hc, RBC, WBC, total protein, albumin; ⬆ survival and immune response to *Yersinia ruckeri* infection | [13]      |
| EtOH extract          | 200 mg/kg, 31 days       | *Sargassum horneri*   | male C57BL/6 mouse; in vivo anti-DNP-IgE i.v. + DNP i.n. challenge | allergy            | ↓ nasal rubbing, ↓ mast cell degranulation; Proposed mechanism: Chlorophyll-C2 → ↓ PI-3K + ↓ Btk, ↓ Syk active upon FcεR trigger → ↓ Ca-mobilization | [15]      |
| EtOH extract          | 10, 50, 100 mg/kg, 1×/day, 3 weeks | *Sargassum horneri*   | female NC/Nga mouse; house dust mite/day NCB skin sensitization DNBC skin challenge (2×/week) | allergy            | ↓ atopic dermatitis symptoms; ↓ epidermal hyperplasia, hyperkeratosis, skin dryness; ↓ mast cell + eosinophil skin infiltrates ↓ Rantes (CCL5), Eotaxin (CCL11), TARC (CCL17) in skin ↓ IL-4, -5, -13, ↓ IL-6, -10, IFN-γ in serum ↓ spleen size increase ↓ IgG1, IgG2a increase | [16]      |
Table A1. Cont.

| Compound/Format | Effective Concentrations | Algal Source | Experimental Model | Inflammatory Phase 1 | Significant Findings 2 | Reference |
|-----------------|--------------------------|--------------|--------------------|---------------------|------------------------|-----------|
| EtOH extract    | 100–300 mg/kg/day in diet, 5 weeks | *Costaria costata* | male NC/Nga mouse; DNCB-induced atopic dermatitis skin allergy | allergy | ↓ inflammatory cell and mast cell infiltration, epidermal thickness, erythema, hemorrhage, dead skin cell layers, skin dehydration | ↓ Epotaxin and TARC (CCL17), ↓ serum IgE and histamine normalization of spleen lymphocyte proliferation and cytokine production | [17] |
| water extract   | 100–300 mg/kg/day, 4 weeks | *Laminaria japonica* | female NC/Nga mouse; DNCB-sensitized and challenged dorsal skin | allergy | ↓ dermatitis severity; ↓ inflammatory mediators | ↑ skin moisture in vitro: ↓ p38 MAPK, ↑ ERK, ↓ STAT1 in HaCaT human keratinocyte cell line | [18] |
| dried powder    | 1–5–10%, 6 weeks | *Eisenia (=Ecklonia) arborea* | female Brown Norway rat; oral OVA immunization | allergy | ↓ OVA-specific IgE, ↓ total IgE (n.s. with 10% diet) | ↓ serum histamine ↑ IFN-γ in spleen and MLN ↓ IL-10 in spleen and MLN | [14] |
| EtOH extract    | 0.1–0.3 g/kg/day, 3 days prior to experiment | *Laminaria japonica* | male SD rat; carrageenan-induced paw inflammation | 1,2 | ↓ paw swelling, leukocyte infiltration in vitro: ↓ IkB phosphorylation → ↓ iNOS, COX2, TNF-α, IL-1β, IL-6 | ↓ ear swelling by arachidonic acid, TPA, oxazolone in vitro: ↓ mast cell degranulation by inhibiting PLA2, COX2, LOX, HA | [19] |
| diethylether fraction | 0.1–1 mg/mouse, 2 x | *Sargassum fusiforme* | ICR mouse; ear-swelling after irritant | 1,2 | ↓ LPS-induced iNOS expression and NO production | ↓ LPS-induced tumoricidal activity against B16 melanoma | [20] |
| ethyl acetate extract | 200 mg/kg, 5 weeks | *Eisenia bicyclis = Ecklonia bicyclis* | male SD rat; isolated peritoneal Mφ | 1,2 | ↓ NF-κB nuclear translocation with and without LPS =(LPS-induced) tumoricidal activity against B16 melanoma | [21] |
| Compound/Format | Effective Concentrations | Algal Source | Experimental Model | Inflammatory Phase | Significant Findings | Reference |
|-----------------|--------------------------|--------------|--------------------|-------------------|----------------------|-----------|
| EtOH extract +/− enzyme-treatment | 50–200 mg/kg, 3 weeks | *Hizikia = Sargassum fusiforme* | male C57BL mouse; LPS-stimulation of isolated peritoneal Mφ conA-induced splenic lymphocyte proliferation | 1,2 | ↑ LPS-stimulated IL-1β, TNF-α, IL-6 by peritoneal Mφ; ↑ conA-induced splenocyte proliferation | [22] |
| EtOH extract | 6–24 mg/kg/day, 4 days | *Sargassum serratifolium* | male ICR mouse; LPS i.p. (2 mg/kg), blood sampling after 2 h | 1 | ↓ TNF, IL-1β, IL-6 confirming in vitro findings | [23] |
| enzymatic extract | 50–200 µg/mL, 1 h prior to and during exp | *Sargassum polycystum Chnoospora minima* | zebrafish embryos; in vivo 24 h challenge w/ H₂O₂ (10 µg/mL) or LPS (10 µg/mL), monitored 5d | 1,2 | ↓ H₂O₂-induced ROS levels and cell death; ↓ LPS-induced ROS, NO and cell death | [24] |
| whole seaweed | 0–4% feed, 40 days | *Sargassum latifolium* | Barki sheep (*Ovis aries*); i.v. LPS challenge (1.25 µg/kg), after day 28 + day 35 | 2 | ↓ body temperature, respiration rate; ↓ leukocytosis, ESR, HSP70; ↑ blood anti-oxidant capacity (CAT, SOD); ↓ damage-related molecules: malondialdehyde (MDA; lipid peroxidation product); ALAT, LDH | [25] |
| whole seaweed | 0–4% feed, 40 days | *Sargassum latifolium* | Barki sheep (*Ovis aries*); heat stress (solar experiment 8–17) vs. mild temperature without solar exposure | 2,3 | ↓ Δ leukocytosis, Δ ESR; ↓ proinflammatory cytokines, HSP70; ↑ body weight gain, kidney function, blood anti-oxidant function | [26] |
| Compound/Format | Effective Concentrations | Algal Source | Experimental Model | Inflammatory Phase | Significant Findings | Reference |
|----------------|-------------------------|--------------|--------------------|-------------------|----------------------|-----------|
| commercial extract | 1% feed, 27 days prior to and during exp (10 days) | *Ascophyllum nodosum* | crossbred wether lamb (*Ovis aries*); heat stress | | ↓ heat stress-induced reduction of phagocyte oxidative burst ↑ SOD ↓ heat stress-induced changes in GSH-peroxidase activity ↓ lipid peroxidation ↑ leukocyte phagocytosis | [27] |
| EtOH and organic-purified fraction | 15 mg/kg/day, 6 weeks | Turbinaria ornata | female C57BL/6J mouse; DSS-induced colitis | | ↓ disease activity index ↓ histopathology incl. length reduction, neutrophil infiltrate ↓ TNF ↑ FoxP3, Treg, but = Th17 ↑ IL-10 | [28] |
| aqueous extract (AE) + probiotic mix | 100–300 mg/kg, 2×/day for 7 days | Laminaria japonica | male BALB/c mouse; DSS-induced colitis | | AE alone: ↓ colitis, incl. ↓ colonic IL-1, IL-6 AE + probiotics: synergistic ↓ colitis, ↓ IL-1, -6, -12p40; not IFN-γ, IL-10, IL-12p70 | [29] |
| EtOH-extract | 50–200 mg/kg/day, d.28–98 | Sargassum muticum | male DBA/1J mouse; collagen-induced arthritis | | ↓ arthritis and edema ↓ IL-6, TNF, IFN-γ in serum ↓ joint degradation, inflammatory cytokines in joints possibly explained by apo-9′ fucoxanthinone (sim. effects) | [30] |
| GFS = hot water extract with galactofucan sulfate | therapy: 4 × 560 mg/day, 10 days, 1–24 mo. maintenance: 2 × 560 mg/day | Undaria pinnatifida | human; response in patients with active or latent Herpes infection | | 15/15 patients with active disease: ↓ symptoms or full clearance of infection no side effects inhibition of relapse in pts with latent disease | [31] |
Table A1. Cont.

| Compound/Format | Effective Concentrations | Algal Source | Experimental Model | Inflammatory Phase | Significant Findings | Reference |
|-----------------|--------------------------|--------------|--------------------|--------------------|----------------------|----------|
| hot water extract, and HCl-EtOH extract | 100 mg/kg/day (heat extract), 10 mg/kg/day (HCl-EtOH extract), for 3–7 days | Laminaria japonica | kuruma shrimp (Marsupenaeus japonicas) in vivo WSSV infection in vitro hemocyte analysis | 1,2 | ↑ survival upon WSSV infectionhemocyte fMet-Leu-Phe stimulation: ↑ chemotaxis ↑ superoxide production ↑ phenol oxidase activity ↑ phagocytosis | [32] |
| hot water-EtOH extract | 20–200 mg/kg; 7 weeks | Hizikia. = Sargassum fusiforme | male SD rat; ligature-induced periodontitis | 3 | ↓ alveolar bone loss due to inflammation | [33] |
| hot water extract of 10 different herbs incl. S. fusiforme | 10 mg/kg; 10 weeks | Sargassum fusiforme | female SD rat; induced autoimmune thyroiditis by CFA-IFA thyroglobulin immunization | 3 | ↓ AI-thyroiditis (cellular infiltrate), ↓ auto antibodies | [34] |
| whole seaweed, freeze-dried, powdered | 5% in chow, 8 weeks | Undaria pinnatifida | male C57BL/6J mouse, HFD+/− seaweed supplement | 3 | ↑ total plasma cholesterol (cf. HFD) fecal cholesterol excretion ↓↓ MCP-1 induction obese phenotype not prevented no glycemic improvement in i.p. glucose tolerance test microbiome composition (HFD + seaweed) is closer to LFD than to HFD | [38] |
Table A1. Cont.

| Compound/Format | Effective Concentrations | Algal Source | Experimental Model | Inflammatory Phase | Significant Findings 2 | Reference |
|-----------------|--------------------------|--------------|---------------------|--------------------|------------------------|----------|
| whole seaweed, freeze-dried | 5% in chow, 16 weeks | Undaria pinnatifida (Up), Laminaria japonica (Lj), Sargassum fulvellum (Sf), Hizikia = (Sargassum) fusiforme (Hf) | male C57BL/6N mouse, HFD+/− seaweed supplement | 3 | body weight or adiposity: no change cf. HFD, except HFD+Up →↑ weight + ↑ subcutaneous adipose tissue adiponectin: ↓ with HFD+Up leptin: ↓ with HFD+Lj, +Sf, +Hf insulin resistance: ↓ w/HFD+Lj blood glucose: ↓ HFD+Lj or +Hf = LFD; HFD+Up = HFD crown-like structures in adipose tissue: ↓↓ with all; =LFD LPS-induced pro-inflammatory cytokines by BMDM: ↓ with all | [36] |
| MeOH extract + carob pod | 0.1%/0.9%, 4 weeks | Undaria pinnatifida | male Wistar rat, MetS after 8 weeks western diet | 2,3 | =body weight, fat mass or muscle =food or energy intake ↓ systolic blood pressure at low dose; ↑ at high dose =CRP ↑ insulin, =glucose ↓ non-esterified fatty acids | [37] |
| hot aqueous extract | 500 mg/kg/day started after 2 weeks, for 2 weeks | Ecklonia cava | female Sprague Dawley rat, letrozole-induced PCOS | 2,3 | ↓ vaginal leukocyte infiltration restore normal estrous cycle restore normal plasma hormonal levels normalize expression of gonadotropin- and steroid hormone-related genes = weight gain upon PCOS induction | [39] |

1 Phases of inflammation as indicated in Table 1: 1-initiation of inflammation; 2-short term amplification and regulation; 3-short- or long-term consequences. 2 Symbols used: ↑—increase; ↓—decrease; =—no change.
### Appendix B

**Table A2.** Effects of oral supplementation of brown seaweed derived polysaccharides on inflammation-related parameters.

| Compound/Format | Effective Concentrations | Algal Source | Experimental Model | Inflammatory Phase | Significant Findings | Reference |
|-----------------|--------------------------|--------------|--------------------|-------------------|----------------------|-----------|
| Fucoidan        | 0.2%, 2% fucoidan chow for 8 weeks | *Cladosiphon okamuranus* | Rats | steady state | Uptake through intestinal tract | [46] |
| Fucoidan 7 kDa (LMW) | 2000 mg/kg, Single dose | *Ascophyllum nodosum* | rats | steady state | No toxicity | [50] |
| Sodium-Alginate (SA) | 5% SA containing chow for 6 weeks | Unknown | Male C57BL/6, Non-alcoholic steatosis model | steady state | ↑ Intestinal barrier function in small intestine, ↓ Hepatic lipid accumulation, Liver: ↓ TNFα, ↓ Collagen-1α1, Liver: ↓ Macrophage infiltration | [162] |
| Fucoidan-rich extract | 50–100–150 mg/kg for 14 days | *Undaria pinnatifida* | In vitro: RAW 264.7, In vivo: C57BL/6 mice | steady state | In vitro: ↑ NO, ↑ TNF-α, IL-1α, IL-1β, IL-6, In vivo: ↑ CD3+, CD4+, ↑ TNF-α, IFN-γ, ↑ IgM | [163] |
| Fucoidan | 10–100 mg/kg for 21 days | *Cladosiphon tokida* | In vitro: RAW 264.7 + S180 tumor cells, In vivo: S180 tumor bearing mice | steady state | ↑ NO-production by macrophages, ↑ NK-cell mediated cytotoxicity, ↑ NF-κβ translocation in macrophages | [52] |
| Fucoidan-rich extract | 50–100–150 mg/kg for 14 days | *Undaria pinnatifida* | Cyclophosphamide-immunosuppressed male C57BL/6 mice | steady state | All doses: ↑ NK cytotoxicity, 100–150 mg/kg: ↑ proliferation of T cells, 150 mg/kg: ↑ TNF-α, IgM and total IgG | [93] |
| Extracted polysaccharides (SFP) | 100–200–300 mg/kg, 14 days | *Sargassum fusiforme* | Cyclophosphamide-immunosuppressed ICR mice | steady state | Compared to the cy model group: ↑ Thymus and spleen indices, Liver: ↑ SOD, ↓ MDA, ↑ GSH, ↑ villus height in normal mice, = in CY-treated mice | [164] |
| Compound/Format | Effective Concentrations | Algal Source      | Experimental Model                                                                 | Inflammatory Phase 1 | Significant Findings 2 | Reference |
|-----------------|--------------------------|-------------------|-------------------------------------------------------------------------------------|----------------------|------------------------|-----------|
| Fucoidan        | Buccal LPS injection on 3 separate days followed by fucoidan ingestion *P. gingivalis* infection day 10–25, followed Fucoidan ingestion day 29–49 | *Sargassum wightii* | Mouse–Buccal LPS and bacterial (*P. gingivalis*) induced inflammation In vitro: RAW 264.7—LPS induced inflammation | 2                    | ↓ TNF-α, IL-1β, IL-6 ↓ monocyte and dendritic cell recruitment =lymphocyte numbers ↓ IL-17, ↑ IL-10 ↓ inhibited antigen-specific immune response No inhibition of bacterial induced periodontitis In vitro: ↓ iNOS, COX-2 ↓ NO, PGE2 ↓ TNF-α, IL-6, IFN-γ | [55]      |
| Sulfated polysaccharide >30 kDa | 25–50–100 µg/mL | *Sargassum horneri* | Zebrafish embryos—LPS induced inflammation In vitro: RAW 264.7—LPS induced inflammation | 1,2                  | ↓ LPS-induced NO production, toxicity, cell death In vitro: ↓ p-IKβ ↓ iNOS, COX-2 ↓ NO, PGE2 ↓ TNF-α, IL-6 | [56]      |
| Fucoidan        | 25–50–100 µg/mL          | *Fucus vesiculosus*| Zebrafish embryos—LPS induced inflammation In vitro: RAW 264.7—LPS induced inflammation | 1,2                  | ↓ NO, ROS production ↓ neutrophil and macrophage recruitment ↓ dose dependent activity In vitro: ↓ iNOS, COX-2 ↓ NO, PGE2 ↓ TNF-α, IL-1β | [103]     |
| Fucoidan        | 12.5–25–50 µg/mL         | *Turbinaria ornata*| Zebrafish embryos—LPS induced inflammation In vitro: RAW 264.7—LPS induced inflammation | 1,2                  | ↓ NO, ROS production ↑ Cell viability ↓ dose dependent activity In vitro: ↓ iNOS, COX-2 ↓ NO, PGE2 ↓ TNF-α, IL-1β | [53]      |
| Fucoidan        | 12.5–25–50 µg/mL         | *Laminaria japonica*| Zebrafish embryos—LPS induced inflammation In vitro: RAW 264.7—LPS induced inflammation | 1,2                  | ↓ NO, ROS production ↓ cell death rate ↓ dose dependent activity In vitro: ↓ MAPK, NF-κβ ↓ NO, ↓ TNF-α, IL-1β, IL-6 | [54]      |
Table A2. Cont.

| Compound/Format                        | Effective Concentrations | Algal Source | Experimental Model | Inflammatory Phase | Significant Findings | Reference |
|----------------------------------------|--------------------------|--------------|--------------------|--------------------|----------------------|-----------|
| Laminarin, fucoidan and ash            | Laminarin 1 g, fucoidan 0.8 g, day 107 of gestation until weaning (day 26) | Laminaria | Pregnant + Lactating sows | 2 | ↑ Colostrum IgA, ↑ Piglets serum IgG | [64] |
| Fucoidan                               | 6 g/kg feed for 21 days | Laminaria japonica | Immunosuppressed African catfish | 1,2 | Macrophages: ↑ oxidative burst, ↑ phagocytic activity | [70] |
|                                        |                          |              |                    |                    | Lymphocytes: ↑ transformation index | |
|                                        |                          |              |                    |                    | Serum: ↑ lysozyme, NO and bactericidal activity | |
|                                        |                          |              |                    |                    | ↑ Survival rate in challenge test | |
| Fucoidan-rich extract                   | 2% inclusion, 45 days feeding trial | Sargassum wightii | Sutchi Catfish | 1,2 | Macrophages: ↑ oxidative burst, ↑ phagocytic activity | [73] |
|                                        |                          |              |                    |                    | ↑ Total lymphocyte count | |
|                                        |                          |              |                    |                    | ↓ Albumin/Globulin ratio | |
|                                        |                          |              |                    |                    | ↑ IFN-γ | |
|                                        |                          |              |                    |                    | ↑ Survival rate in challenge test | |
| Laminarin                              | 0.2 g/kg/day for 21 days | Laminaria digitata | Rainbow trout | 1,2 | ↑ TNF-α, IL-8 | [72] |
| Fucoidan                               | 0.05%, 0.1% and 0.2% per kilogram feed | Sargassum horneri | Yellow catfish | 1,2 | Macrophages: ↑ oxidative burst, ↑ phagocytic activity | [75] |
|                                        |                          |              |                    |                    | Serum: ↑ lysozyme | |
|                                        |                          |              |                    |                    | ↑ CAT, ↑ SOD, ↓ MDA | |
|                                        |                          |              |                    |                    | ↑ Survival rate in challenge test | |
| Fucoidan-rich seaweed extract (FRSE) + Methionine | 2% FRSE + 0.3 methionine | Sargassum wightii | Carp (Labeo rohita) | 1,2 | ↑ respiratory burst activity, phagocytic activity, | [71] |
|                                        |                          |              |                    |                    | ↑ MPO activity, lysozyme activity, | |
|                                        |                          |              |                    |                    | ↑ total immunoglobulin and TLC | |
| Laminarin                              | 0.5–1.0% inclusion in diet for 48 days | Commercially sourced | Grouper (Epinephelus coioides) | 1,2 | ↑ IL-1β, IL-8 and TLR2 | [76] |
|                                        |                          |              |                    |                    | ↑ lysozyme, CAT and SOD | |
|                                        |                          |              |                    |                    | ↑ growth rate and the feed efficiency | |
Table A2. Cont.

| Compound/Format                  | Effective Concentrations | Algal Source                          | Experimental Model | Inflammatory Phase | Significant Findings | Reference |
|---------------------------------|--------------------------|---------------------------------------|--------------------|-------------------|----------------------|-----------|
| Fucoidan                        | 250–500 mg/kg feed       | Sargassum, Padina and Turbinaria      | White shrimp       | 1,2               | ↑ THC, PA and SOD ↑ LGBP, Toll and lectin | [74]      |
| Laminarin, fucoidan and ash     | Lam 1 g, Fuc 0.8 g, d 83 of gestation until weaning (day 28) | Laminaria          | Pregnant + Lactating sows | 1,2               | ↑ Piglets villus height in the jejunum and ileum | [67]      |
| Extract                         | D 83 of gestation until weaning (day 28) | Ascophyllum nodosum and Fucus | Pregnant + Lactating sows | 1,2               | ↑ Piglets CD4+ and CD8+ T cells | [66]      |
| Laminarin                      | 1 g/day Pre-weaning (0–62 days) and post-weaning (63–93 days) | Laminaria          | Holstein Friesian bull calves | 1,2               | ↓ Growth ↑ serum haptoglobin ↓ lymphocyte levels ↓ stimulated IFN-γ (in vitro challenges) | [68]      |
| Sodium alginate oligosaccharides | 0, 0.04 and 0.2% of diet | Unknown                              | broiler chickens Salmonella Enteritis challenge | 1,2               | in unchallenged animals: ↑ IFN-γ, IL-10, IL-1β | [69]      |
| Highly viscous polysaccharide extract (HVPE) | 10–30–100 mg/kg/day for 14 days | Kjellmania crassifolia | C57BL/6 mice | 1,2 | ConA-stimulated spleen cells: ↑ IFN-γ, IL-12, IL-6, IgA secretion ConA-stimulated Peyer’s patch cells: ↑ IgA ↑ Peritoneal macrophage phagocytic activity | [77]      |
| Fucoidan (LMWF)                 | 200–400–1000 mg/kg/day (6 weeks) | Laminaria japonica | Sprague Dawley rats, Mycoplasma pneumoniae antigen stimulation | 1,2               | ↑ Spleen weight, splenocyte proliferation potential ↑ NK cell activity, ↑ Phagocytic activity ↑ IFN-γ, IL-2 IL-4 ↑ IgG, IgA ↓ IgE ↑ Antigen-specific antibodies | [61]      |
| Fucoidan containing product (88.3% purity) | 410–1025 mg/kg | Cladosiphon okamuramus | Balb/c mice, OVA-immunized | 1,2               | ↑ Immune cell proliferation, IL-2, ↑ macrophage phagocytic activity ↑ serum IgM, IgG, IgA ↓ IgE ↓ IL-4, -5 | [62]      |
Table A2. Cont.

| Compound/Format | Effective Concentrations | Algal Source | Experimental Model | Inflammatory Phase | Significant Findings | Reference |
|-----------------|--------------------------|--------------|--------------------|--------------------|----------------------|-----------|
| Fucoidan (LMWF, MMWF, HMWF) | Unclear | Cladosiphon okamuranus | Pathogen free Male Balb/c mice | 1,2 | HMWF: ↑ Proportion CD8+ T-cells in spleen, ↓ CD4/CD8 ratio | [78] |
| water-soluble polysaccharides | 50–100–200 for 10 days | Sargassum fusiforme | Cyclophosphamide-immunosuppressed ICR mice | 1,2 | Compared to the cy model group: ↑ spleen index, ↑ splenic lymphocyte proliferation potential, ↑ splenocyte produced IL-2, IL-6, IFN-γ, peritoneal macrophages, ↑ phagocytic activity, ↑ produced IL-2, IL-6, IFN-γ | [92] |
| Fucoidan | 150 mg/kg daily for 2 weeks | Fucus vesiculosus | mice | 1,2 | increased cytolytic activity of NK cells | [89] |
| Laminarin | 500–1000 mg/kg/day for 10 days | Unknown, commercially sourced | Cyclophosphamide-immunosuppressed male Balb/c mice | 1,2 | Compared to the cy model group: ↑ cytotoxicity of NK cells, ↑ serum IL-12 and IFN-γ | [94] |
| Fucoidan | 0.1–0.5 mg/day for 14 days | Undaria pinnatifada | HSV-1 infected mice/fluorouracil immunosuppressed mice | 2 | Protection against herpes infection: ↑ Macrophage NO production, ↑ CTL activity, ↑ B-cell blastogenesis, ↑ Antibody titers | [82] |
| Fucoidan | 25–250 mg/kg/day, 3 times weekly for 4 weeks | Unknown | Leishmania infection, Balb/c mice | 3 | In vitro: 93% reduction Amastigote multiplication in macrophages. In vivo: complete elimination parasite in liver and spleen. Th2 ♦ Th1 response. Splenocytes: ↑ superoxide and NO production. | [79] |
| Fucoidan | 500 mg/kg every 2 days, for 6 weeks | Fucus vesiculosus | Schistosomiasis Japonica infected C57BL/6 mice | 3 | ↓ Granuloma size, ↓ hepatic inflammation. ↓ IL-6, IL-12, TNF-α, ↑ IL-4, IL-13, ↑ IL-10, TGF-β, ↑ Th2 response, ↑ Treg infiltration in liver. | [106] |
| Compound/Format                  | Effective Concentrations | Algal Source            | Experimental Model                                                                 | Inflammatory Phase | Significant Findings                                                                                             | Reference |
|---------------------------------|--------------------------|-------------------------|-------------------------------------------------------------------------------------|-------------------|----------------------------------------------------------------------------------------------------------------|-----------|
| Fucoidan                        | 0.034 g/mouse/day 10 days before, 40 days after tumor inoculation | Undaria pinnatifida     | A20-tumor bearing Male Balb/c mice/Do-11-10-Tg mice (transgenic for TCR)            | 3                 | ↑ NK cell activity, ↑ CTL activity, ↑ IFN-γ, IL-12                                                              | [84]      |
| Ascophyllan                     | 500 mg/kg, 4 days before–10 days after tumor implantation      | Ascophyllum nodosum     | S-180 sarcoma bearing SPF male ddY mice                                             | 3                 | Oral route stronger anti-tumor effects than intraperitoneal injection, effects via interaction with intestinal immune system ↓ 69% tumor size reduction ↑ TNF-α, IL-12                       | [91]      |
| Polysaccharides                 | 100–200 mg/kg for 28 days                                    | Sargassum fusiforme     | A549 adenolungcarcinoma-bearing Balb/c mice                                         | 3                 | ↑ Serum TNF-α, ↑ Peritoneal macrophage production of TNF-α, IL-1β ↑ Splenocyte lymphocyte proliferation Liver and Kidney: ↑ SOD, ↓ MDA                                                                 | [87]      |
| Fucoidan (LMWF/IMWF/HMWF)       | 5 g/kg/day                                                           | Cladosiphon okamuramus  | Colon 26 tumor bearing mice; Myd-88−/− mice                                        | 3                 | No intestinal absorption Effects via interaction with intestinal immune system All: ↑ Median survival timeLMWF ↓ Tumor weight, ↓ Cell divisions, ↑ Apoptosis HMWF; ↑ Splenic NK cell numbers | [85]      |
| Polysaccharide                  | 100–200–400 mg/kg for 28 days                                   | Sargassum fusiforme     | HepG2-tumor-bearing mice                                                            | 3                 | ↑ Serum NO, IL-1β, IgM ↑ Peritoneal macrophage production of TNF-α, IL-1β ↑ Apoptosis in HepG2-tumor cells                                                   | [86]      |
| Polysaccharides                 | 50–100–200 mg/kg                                                  | Sargassum fusiforme     | CNE- tumor-bearing mice                                                              | 3                 | ↑ Serum NO, IL-1β, IgM ↑ Peritoneal macrophage production of NO, IL-1β↑ Splenocyte lymphocyte proliferation ↑ IgM production Activity is, in part, mediated via TLR2 and TLR4                                      | [88]      |
| Compound/Format | Effective Concentrations | Algal Source | Experimental Model | Inflammatory Phase ¹ | Significant Findings ² | Reference |
|-----------------|--------------------------|--------------|--------------------|----------------------|------------------------|----------|
| Fucoidan        | 200–400 mg/kg (6×/week) for 4 months | *Fucus vesiculosus* | DMBA-induced mammary carcinogenesis in female Sprague Dawley rats | 3 | ↓Tumor incidence, ↓Tumor weight ↑Serum IL-6, IL-12p40, IFN-γ ↓IL-10 TGF-β ↓MRNA expression levels of FOXP3, TGF-β, ↑IFN-γ in tumors ↓Foop3, PD1, =PDL1/PDL2 protein levels in tumors ↓p-PI3K, p-AKT protein levels in tumors | [90] |
| Fucoidan        | 5 mg/day for 10 days (start direct after infection) | *Undaria pinnatifida* | Influenza infected mice | 3 | ↑Survival ↑Inhibition of viral replication ↑Mucosal antibody levels (IgA) ↑Serum antibody titer (IgM, IgG) | [80] |
| Fucoidan        | 6 g/day for 6–13 months | Unknown, commercially obtained | Human, HTLV-infected patients | 3 | ↓HTLV proviral load =CD4⁺, CD8⁺ frequencies =NK-cell, mDC and pDC frequencies | [81] |
| Oligo Fucoidan  | 4400 mg/day for 48 weeks | Unknown, commercially sourced | Patients with chronic Hepatitis B virus 2193 | 3 | vitamin D dependent activity ↓HBV DNA ↑CD4⁺CD45RO⁺ and CD8⁺CD45RO⁺ | [109] |
| Fucoidan        | 3 g/day for 6 months | *Cladosiphon okamuranus* | Human, male cancer survivors | 3 | ↑NK-cell activity | [165] |
| Fucoidan        | 100–1000 mg/day for 4 weeks | *Fucus vesiculosus* (85%), *Macrocystis pyrifera* (10%), *Laminaria japonica* (5%) | Human volunteers | 3 | ↑Cytotoxic T cell numbers ↑Phagocytic capacity monocytes ↓IL-6No dose response | [110] |
| Fudoidan (75% pure) | 3 g/day for 12 days | *Undaria pinnatifida* | Human volunteers | 3 | ↑CD34⁺ cells, CD34⁺ cells expressing CXCR4 (45% ♦ 90%)↑ serum SDF-1 and IFN-γ | [166] |
| Fucoidan        | 300 mg/day for 4 weeks | *Mekabu fucoidan* | Human, Influenza vaccinated elderly | 3 | ↑Antibody titers | [167] |
### Table A2. Cont.

| Compound/Format                  | Effective Concentrations | Algal Source               | Experimental Model                              | Inflammatory Phase $^1$ | Significant Findings $^2$                                                                 | Reference |
|----------------------------------|--------------------------|---------------------------|------------------------------------------------|-------------------------|------------------------------------------------------------------------------------------|-----------|
| Sulphated polysaccharide         | 20–40–80 mg/kg/day for 5 days | *Sargassum hemiphyllum*   | Mouse–arachidonic acid induced ear-inflammation | 2                      | ↓ Ear swelling and erythema ↓ TNF-α, IL-1β, IL-6 ↓ neutrophil infiltration             | [95]      |
| Combined preparation             | Fucoidan: 18–54 mg/kg/day for 7 days | *Laminaria japonica*     | Mouse–Carrageenan induced pouch inflammation  | 2                      | ↓ NO, PGE2 ↓ neutrophil and macrophage recruitment                                      | [96]      |
|                                  |                          |                           |                                                 |                         | Protection against ulceration ↓ AST, ALT ↓ PGE2 ↓ IFN-γ, IL-6, IL-10 ↓ stomach glycogen | [97]      |
| Fucoidan                         | 0.02 g/kg for 14 days    | Commercially sourced from Sigma | Mouse–aspirin induced ulcer                    | 2,3                    | Oral synergy best results ↑ colon length ↓ colon weight/body weight, spleen weight ↓ Histology damage score ↓ TNF-α, IL-12 IP fucoidan actually worsened colitis symptoms | [99]      |
| Fucoidan                         | 0.05% w/w in chow        | *Cladosiphon okamuranus*  | Mouse–DSS-induced colitis                     | 2                      | ↓ IFN-γ, IL-6 ↑ IL-10, TGF-β                                                           | [98]      |
| Fucoidan & Fucoidan-polyphenol   | 10 mg/mouse, 400 mg/kg/day | *Fucus vesiculosus*       | Mouse–DSS-induced colitis                     | 2,3                    | ↓ myocardial infarct size ↓ HMGB1, p-IκBα and NF-κB ↓ TNF-α and IL-6, ↑ IL-10 ↓ infiltration PMNs, ↓ MPO activity ↓ histopathological damages in myocardium | [100]     |
| complex (Synergy)                |                          |                           |                                                 |                         |                                                                                       |           |
| Fucoidan                         | 200 mg/kg                | *Laminaria japonica*      | Mouse–myocardial ischemia-reperfusion injury  | 2,3                    | ↓ Lung fibrosis ↓ Neutrophil and macrophage infiltration ↓ TIMP-1, CXCL-1, MCP-1, MIP-2, IL-Ra ↓ Procollagen-1α | [105]     |
| Fucoidan                         | 200 mg/kg/day for 14 days | *Sargassum hemiphyllum*   | C57BL/6 mice, irradiation induced pneumonitis and lung fibrosis | 3                      |                                                                                       |           |
| Compound/Format | Effective Concentrations | Algal Source | Experimental Model | Inflammatory Phase | Significant Findings | Reference |
|----------------|--------------------------|--------------|--------------------|-------------------|----------------------|-----------|
| Fucoidan  (LMWF: 1 ± 0.2 kDa MMWF: 3.5 ± 0.3 kDa HMWF: 100 ± 4 kDa) | 300 mg/kg dissolved in water, one day after booster immunization until the end of the experiment (day 22–47) | Undaria pinnatifada | Male DBA/1J mice, Collagen-induced arthritis | 2,3 | LMWF: ↓ reduced severity of inflammation ↓ IFN-γ, TNF-α ↓ IgG2a, HMWF: ↑ increased severity of inflammation ↑ IFN-γ, TNF-α ↑ IgG2a ↑ adhesion molecules and migration potential of macrophages | [102] |
| Fucoidan | 4 g/day for 4 at least weeks | Cladosiphon novae Caledoniae | Advanced cancer patients | 3 | Responsiveness of IL-1β independent prognostic factor for QOL-scores ↓ TNF-α, IL-1β, IL-6 = QOL-scores | [111] |
| Fucoidan | 400 mg/kg for 22 weeks | Fucus vesiculosus | Mice, colorectal carcinogenesis model | 2,3 | ↑ Beneficial Microbiome modulation ↓ IL-17 and IL-23 ↑ IFN-γ, IL-4 and IL-10 ↑ NK cells, CD4+ T cells in blood | [101] |
| Fucoidan | 300–600 mg/kg/day for 5 weeks | Fucus vesiculosus | Non-obese diabetic mice (autoimmune diabetes model) | 2 | ↑ serum insulin levels Delayed onset and ↓ incidence of diabetes ↓ Th1 cytokines ↑ Th2 cytokines Dendritic cells: ↓ MHC-II, ↓ CD86 Pancreatic cells: ↓ TLR4 expression Microbiota: ↑ Akkermansia, ↑ Lactobacillus, ↓ Bacteroides | [108] |
| Fucoidan | 400 mg/kg | Ascophyllum nodosum | Colonic inflammation-induced SPF-C57BL/6 mice (antibiotics treated) | 3 | ↓ Colonic inflammation ↓ Dysbiosis ↓ Infiltration of inflammatory cells ↓ Space between mucosa and submucosa ↑ Crypt depth ↓ TNF-α, IL-1β, IL-6, ↑ IL-10 | [100] |
| Fucoidan | 200 mg/kg | Laminaria japonica/Ascophyllum nodosum | SPF C57BL/6 J mice, High fat diet | 3 | ↓ Body weight gain, ↓ Fat mass ↓ Insulin resistance ↓ Endotoxemia (↓ LBP) ↓ Systemic inflammation (↓ TNF-α, IL-1β, MCP-1) Microbiome: ↑ Akkermansia, Alloprevotella, Blautia, Bacteroides | [47] |
| Compound/Format          | Effective Concentrations | Algal Source          | Experimental Model                          | Inflammatory Phase | Significant Findings                                                                 | Reference |
|-------------------------|--------------------------|-----------------------|--------------------------------------------|--------------------|--------------------------------------------------------------------------------------|-----------|
| Fucoidan and Fucoxanthin| 275 mg LMF               | Unknown, commercially obtained | Clinical trial, NAFLD patients             | 1                  | ↓ AST = adiponecitin                                                                     | [168]     |
|                         |                          |                       |                                            |                    | ↓ AST, ALT                                                                             |           |
|                         |                          |                       |                                            |                    | ↓ Histopathological changes                                                             |           |
|                         |                          |                       |                                            |                    | ↓ IFN-γ, TNF-α                                                                           |           |
|                         |                          |                       |                                            |                    | ↓ Apoptosis inhibition                                                                  |           |
| Fucoidan                | 50 mg/kg for 14 days     | *Fucus vesiculosus*   | Balb/C mice, ConA-induced acute liver injury | 3                  | ↓ AST, ALT                                                                             | [107]     |
|                         |                          |                       |                                            |                    | ↓ Histopathological changes                                                             |           |
|                         |                          |                       |                                            |                    | ↓ IFN-γ, TNF-α                                                                           |           |
|                         |                          |                       |                                            |                    | ↓ Apoptosis inhibition                                                                  |           |
| Fucoidan                | 1 or 5% inclusion in diet (12 weeks) | *Cladosiphon okamuranus* | Diet-induced dyslipidemia in ApoE−/− mice | 3                  | ↓ Tissue weight (liver and WAT), hepatic steatosis                                      | [169]     |
|                         |                          |                       |                                            |                    | ↓ Blood lipids (TC, TG, non-HDL-C)                                                     |           |
|                         |                          |                       |                                            |                    | ↑ Blood glucose                                                                        |           |
|                         |                          |                       |                                            |                    | ↑ Plasma LPL activity, HDL-C                                                             |           |
|                         |                          |                       |                                            |                    | ↑ Insulin-sensitivity                                                                  |           |
|                         |                          |                       |                                            |                    | ↑ Ppara, ↓ Srebfl                                                                         |           |
| LJP12                   | 50–100–200 mg/kg/day     | *Laminaria japonica*  | Atherogenic diet fed LDLR−/− mice          | 3                  | Dose-dependent activity                                                                 | [112]     |
|                         |                          |                       |                                            |                    | ↓ Atherosclerotic plaque formation                                                       |           |
|                         |                          |                       |                                            |                    | ↓ Plasma lipids (TC, TG, LDL-C)                                                         |           |
|                         |                          |                       |                                            |                    | ↑ HDL-C/LDL-C                                                                           |           |
|                         |                          |                       |                                            |                    | ↓ Systemic inflammation (↓ TNF-α, IL-1β, IL-6, MCP-1, ↑ IL-10)                          |           |
|                         |                          |                       |                                            |                    | ↑ SOD, ↓ MDA                                                                            |           |
|                         |                          |                       |                                            |                    | ↓ p-p 65, p-1κβ, p-ERK, p-JNK, p-P38                                                   |           |
| Fucoidan (LMWF)         | 200 mg/kg/day            | *Laminaria japonica*  | Diet-induced dyslipidemia in ApoE−/− mice | 3                  | ↓ TG, OX-LDL                                                                           | [114]     |
|                         |                          |                       |                                            |                    | ↓ p-JNK, cyclin-D1                                                                      |           |
|                         |                          |                       |                                            |                    | ↓ IL-6, ↑ IL-10                                                                         |           |
|                         |                          |                       |                                            |                    | ↓ Macrophages ◇ foam cells                                                              |           |
|                         |                          |                       |                                            |                    | ↓ Migration of SMCs into intimal layer                                                  |           |
| Fucoidan                |                          | *Fucus vesiculosus*   | Rats                                       | 3                  | ↓ Endothelial hyperplasia, ↓ vascular modulation                                        | [115]     |
|                         |                          |                       |                                            |                    | ↓ α-actin⁺ cells                                                                        |           |
|                         |                          |                       |                                            |                    | ↓ Vessel inflammation, ↓ Macrophage infiltration                                       |           |
|                         |                          |                       |                                            |                    | ↓ Apoptosis in vessel wall                                                              |           |
| Compound/Format | Effective Concentrations | Algal Source | Experimental Model | Inflammatory Phase $^1$ | Significant Findings $^2$ | Reference |
|-----------------|--------------------------|--------------|-------------------|------------------------|----------------------------|-----------|
| Fucoidan (LMWF) | 200 mg/kg/day            | Laminaria japonica | Diet-induced dyslipidemia in ApoE<sup>−/−</sup> mice | 3                      | ↓ Inflammatory infiltration ↓ Limit enlargement of AAA ↓ Maximal aortic diameter Preserved elastin ↓ TNF-α, IL-1β, MCP-1 ↓ MMP | [116]     |
| Fucoidan        | 50–100 mg/kg/day         | Laminaria japonica | In vitro: oxLDL treatment RAW264.7 In vivo: Atherogenic diet fed LDLR<sup>−/−</sup> mice | 3                      | In vitro: ↓ oxLDL-induced LOX-1, ↓ TNF-α, IL-1β, IL-6 ↓ ICAM-1, VCAM-1 ↓ ROS In vivo: ↓ Atherosclerotic plaque formation ↑ Plaque stability; ↓ Macrophage infiltration ↓ Plasma lipids (TC, TG, non-HDL-C) ↓ ROS | [113]     |
| Fucoidan (LMWF) | <3 kDa                   | Undaria pinnatifida | Male Balb/c mice. | 2                      | Fucoidan enhances effects of probiotic strain ↑ IFN-γ, TNF-α, IL-6, IL-12 OVA-immunization: ↓ IgE, IL-4, ↑ IFN-γ Desulphated Fucoidan no effects | [170]     |
| Extracted polysaccharide (not fucoidan) | 50 mg/kg/day for 2 weeks | Laminaria japonica | SPF Kunming mice, OVA-immunized asthma model | 2,3                   | ↓ Eosinophils in BALF ↓ lung inflammation; ↓ Serum IgE ↑ IL-12, ↓ TGF-β, IL-13 in BALF and lung | Lin et al. 2015. Multidiscip Respir Med. PMID: 26110056 [58] |
| Compound/Format | Effective Concentrations | Algal Source          | Experimental Model                           | Inflammatory Phase | Significant Findings  | Reference |
|-----------------|--------------------------|-----------------------|----------------------------------------------|--------------------|-----------------------|-----------|
| Fucoidans       | 100–400 mg/kg/day        | Undaria pinnatifida   | OVA-immunized female Balb/c mice, exacerbated allergic asthma | 2,3                | ↓ Infiltration of macrophages, neutrophils, CD4⁺ lymphocytes ↓ Lipid peroxidation ↓ IL-4, ↓ IgE ↓ Mast cell activation, degranulation ↓ Mucus hypersecretion, ↓ Goblet cell hyperplasia | Herath et al. 2020. Molecules. PMID: 32580518 [57] |
| Fucoidan        | 100–400 µg/mouse/day for 4 days | Laminaria japonica | Female Balb/c mice, passive cutaneous anaphylaxis model | 2,3                | ↓ allergic symptoms (Edema) Oral fucoidan anti-allergy effects, IP-fucoidan no effects = Serum IgE, IgG1 ↑ Galectin-9 secretion by intestinal epithelial cells | [59] |
| Fucoidan        | 60 µg/mouse/day for 17 days after OVA-immunization | Laminaria japonica | Female Balb/c mice, OVA-immunized | 2,3                | ↓ allergic symptoms (Rectal temperature reduction) = Serum IgE ↑ Serum galectin-9 ↓ Degranulation of mast cells ↓ IgE-attachment on mast cells | [60] |
| Alginate, 108 kDa | 2 mg alginate one day before every OVA-challenge | Laminaria japonica | OVA-immunized female Balb/c mice, food allergy model | 2,3                | ↓ IL-4, ↓ IgE ↓ Mast cell degranulation, ↓ Histamine ↑ Number of Tregs in spleen ↓ Th0 ◦ Th2 | [63] |

1 Phases of inflammation as indicated in Table 1: 1-initiation of inflammation; 2-short term amplification and regulation; 3-short- or long-term consequences. 2 Symbols used: ↑—increase; ↓—decrease; =—no change.
### Appendix C

Table A3. Effects of oral supplementation of brown seaweed derived phytosterols on inflammation-related parameters.

| Compound/Format | Effective Concentrations | Algal Source | Experimental Model | Inflammatory Phase | Significant Findings | Reference |
|-----------------|--------------------------|--------------|--------------------|--------------------|----------------------|-----------|
| Seaweed extract containing fucosterol | NH: 200 mg/kg<br>EH: 50, 100 and 200 mg/kg; 3 weeks | *Sargassum fusiforme* = Hijiki | Male C57BL/6 mice; ConA activation induced splenocyte proliferation | 1 | ↑ splenocyte proliferation<br>In peritoneal Macrophages: ↓ IL-6<br>↓ IL-1β<br>↓ TNF-α (EH > NH) | [22] |
| Lipid extract containing 24(S)-Saringo-sterol | 50% (w/w), 10 weeks | *Sargassum fusiforme* | APPswePS1ΔE9 Mice, Alzheimer’s disease +/- seaweed supplement | 3 | ↑ LXR-responsive gene expression in CNS<br>↑ ApoE | [118] |
| Fucosterol extract | 25, 50 or 100 mg/kg; 3 days | *Eisenia bicyclis* | Male BALB/c mice, ConA- induced acute liver injury after Fucosterol pretreatment | 1 | ↓ TNF-α<br>↓ IL-6<br>↓ IL-1β<br>↓ NF-κB p65<br>↑ PPARγ expression<br>↑ p-P38 MAPK levels | [117] |
| ethyl acetate extract => Fucosterol | 200 mg/kg; 2 weeks | *Sargassum fusiforme* | NC/N ga male mice, DNBC induced AD-like dermatitis | | ↓ scratching<br>↓ epidermal thickness of dorsal skin<br>↓ mast cells<br>↓ serum level of IgE<br>In cultured splenocytes: ↓ IL-4<br>↓ TNF-α<br>↑ IFN-γ | [171] |

1 Phases of inflammation as indicated in Table 1: 1-initiation of inflammation; 2-short term amplification and regulation; 3-short- or long-term consequences; ^ Symbols used: ↑—increase; ↓—decrease; =—no change.
Appendix D

Table A4. Effects of oral supplementation of brown seaweed derived phenolic compounds on inflammation-related parameters.

| Compound/Format | Effective Concentrations | Algal Source | Experimental Model | Inflammatory Phase | Significant Findings | Reference |
|-----------------|--------------------------|--------------|--------------------|--------------------|----------------------|-----------|
| (poly)phenol-rich seaweed extract | 400 mg; 8 weeks | Asphodelin nodosum | 80 participants; 30-65 years old with a body mass index (in kg/m²) ≥ 25. | Steady state | ↓ DNA damage in obese people | [7] |
| MeOH–EtAc extract => phlorotannin | 100–200 mg/kg/day 3 days before experiment | Eisenia bicyclis = Ecklonia bicyclis | Sprague Dawley rat, platelet aggregation + activation | Steady state | Eisenia bicyclis extract strongly inhibits in vivo platelet aggregation. | [122] |
| MeOH extract=> Eckol | 25, 50, 100 µg/mL, pretreatment 2 h prior to anaphylaxis induction 25, 50, 100 µg/mL, 24 h | Ecklonia cava | BALB/c mice; anti-DNP-IgE induced PCA CS7BL/6 male mice; anti-DNP-IgE and IgE-BSA induced allergic | allergy | ↑ binding of IgE to FcγRI ↓ FcγRI expression ↓ mRNA level of IL-1β, IL-6, TNF-α, IFN-γ ↓ NF-kB nuclear translocation ↓ IκB degradation ↓ secretion of inflammatory mediators, such as histamine, β-hexosaminidase, leukotrienes and prostaglandins ↓ production of Th2-type cytokines, such as IL-4, IL-5, IL-13 (not 25 ug/mL) | [123] |
| MeOH-ethyl acetate extract (crude (72–74%) phlorotannins = phloroglucinol oligomer); | oral 1 × or 2 ×; 0.1, 1 mg/ear | Ecklonia kurome Ecklonia arborea | male ICR mouse; AA induced ear oedema | allergy | inhibitory effects are comparable to known anti-allergic agents presumed mechanisms: inhibition of MC degranulation + inhibition of COX-2 and LOX, and to lesser extent PLA2, activities | [125] |
| Compound/Format | Effective Concentrations | Algal Source | Experimental Model | Inflammatory Phase 1 | Significant Findings 2 | Reference |
|-----------------|--------------------------|--------------|---------------------|----------------------|------------------------|----------|
| (poly)phenol-rich brown algae extract | 100 mg/kg 500 mg/kg; 12 weeks | *Ecklonia cava* | C57BL/6 male mice; HFD+/- seaweed supplement | 1,3 | ↓ MCP1 ↓ TNF-α ↓ IL-1 ↓ COX-2 (slightly decreased) protein level ↓ NF-κB protein level ↓ Body weight ↓ adipose tissue weight ↓ deposition in the liver ↓ TG and TC levels ↓ leptin and adiponectin ratio ↓ Glucose Tolerance Test ↓ Insulin Resistance ↑ protein levels of P-AMPK ↑ SIRT1 protein levels ↑ PGC1α protein levels in the nucleus | [128] |
| A single compound Pyrogallol-Phloroglucinol-6,6-Bieckol from the brown algae ethanoic extract | 2 mg/kg; 4 weeks | *Ecklonia cava* | C57Bl/6N mice; HFD +/- seaweed supplement | 1,2,3 | In visceral fat: ↓ TNF-α mRNA levels ↓ IL-1β mRNA levels ↓ Macrophage infiltration ↓ M1/M2 ratio (CD86 and CD80 lower, CD163 and CD206 higher) ↓ RAGE ↓ RAGE-RAGE Ligand Bonding ↓ Body weight ↓ size of visceral adipocytes ↓ fat mass ↓ serum TG and TC ↓ AGEs, HMGB1 and S100beta secret by adipocytes | [137] |
| Compound/Format                        | Effective Concentrations | Algal Source          | Experimental Model                                | Inflammatory Phase | Significant Findings                                                                 | Reference |
|---------------------------------------|--------------------------|-----------------------|--------------------------------------------------|--------------------|-----------------------------------------------------------------------------------|-----------|
| Polyphenols-rich Ethanol extract       | 200, 400 mg/kg; 7 days   | Sargassum hornieri    | BALB/c female mice; PM induced airway inflammation in allergic asthma | 1,2                | ↓ granulocyte infiltration, ↓ macrophage infiltration, ↓ TLRs expression in lungs, ↓ NF-κB pathway activation, ↓ pro-inflammatory cytokines IL-1β, TNF-α, IL-6 expression in lung, ↑ IL-10 expression in lung, ↓ IL-25, IL-33, IL-8, TGF-β in lung, ↓ cytokines (IL-25, IL-33) in serum | [124]     |
| phlorotannins-rich extract             | PREC (75 and 150) or dieckol (50 and 100 mg/kg; 4 weeks Combination cisplatin (1, 3 or 5 µM) with PREC (35, 50, 75 or 100 µg/mL); 48 h | Ecklonia cava         | BALB/c athymic female nude mice; SKOV3 cells induced ovarian carcinoma | 1                  | PREC: ↓ Akt in ovarian cancer, ↓ NF-κB in ovarian cancer, ↑ intracellular ROS in ovarian cancer, ↓ cisplatin-induced ROS in normal HEK293, ↑ ROS production in SKOV3 cells, the combined treatment of PREC and cisplatin: ↓ ROS production in in SKOV3 cells and normal HEK 293 cells, Dieckol: ↑ pathways cisplatin-induced ROS production, Dieckol: ↓ pathways cisplatin-induced ROS production (slightly) | [129]     |
| Compound/Format | Effective Concentrations | Algal Source | Experimental Model | Inflammatory Phase | Significant Findings | Reference |
|-----------------|--------------------------|--------------|---------------------|-------------------|----------------------|-----------|
| phlorotannin derived from the brown alga | 0.5 and 1.0 mg/kg/day; Pretreatment for 7 days | *Ecklonia stolonifera* | Male Kunming mice; CCl4 induced acute liver injury | 1,2 | ↓ TNF-α <br> ↓ IL-1β <br> ↓ IL-6 <br> ↓ ROS <br> ↑ IL-10 <br> ↑ CD11c+ | [135] |
| Ethyl acetate fraction containing diphloretanthroxydihydroxycarmalol | 6.25, 12.5, 25 µg/mL | *Ishige okamurae* | Zebrafish embryo; FD induced ROS, NO production and cell death | 1,2 | ↓ ROS production <br> ↓ NO production | [134] |
| polyphenol-rich brown algae extract | 25, 50 and 100 µg/mL; pretreatment for 1 h | *Ecklonia cava* | Zebrafish embryos | 1,2 | ↓ ROS expression <br> ↓ NO expression <br> ↓ iNOS | [133] |
| chloroform–methanol extract Apo-9′-fucoxanthinone (AF) | 25, 50 and 100 µg/mL; pretreatment for 1 h | *Sargassum muticum* | Zebrafish embryos | 1,2 | ↓ IL-1β <br> ↓ TNF-α <br> ↓ ROS <br> ↓ COX-2 <br> ↓ NF-κB <br> ↓ MAPK <br> ↓ iNOS <br> ↓ NO | [131] |
| Six purified phlorotannins ((eckol; 6,60-bieckol; 6,80-bieckol; 8,80-bieckol; phlorofucofuroeckol (PFF)-A and PFF-B) | 10, 100, 200 µM | *Eisenia arborea* | ICR mice; AA, TPA and OXA induced ear swelling | 1 | ↓ COX-2 mRNA expression <br> ↓ COX-2 enzymatic activity | [136] |
| Compound/Format | Effective Concentrations | Algal Source | Experimental Model | Inflammatory Phase | Significant Findings | Reference |
|-----------------|-------------------------|--------------|--------------------|-------------------|----------------------|-----------|
| Ethanol extract including Dieckol, 2,7-phloroglucinol-6,6-bieckol (PHB), PFF-A and pyrogallol-phloroglucinol-6,6'-bieckol (PPB) | 2.5 mg/kg; 4 weeks | Ecklonia cava; HFD +/- seaweed supplement | 1,2,3 | ↓ TNF-α | [126] |
| Ethanol extract | 70 mg/kg; 4 weeks | Ecklonia cava | male 57BL/6N mice, HFD +/- seaweed supplement | 1,2,3 | ↓ NF-κB, ↓ TNF-α, ↓ IL-6, ↓ TLR4 expression, ↓ CD11b, ↓ CD86, ↑ CD206, ↓ body weight, ↓ food intake, ↓ fat mass, ↓ leptin resistance, ↑ leptin sensitivity, ↓ PPAR expression, ↓ CEBP expression, ↓ FAS expression, ↓ ACC expression, ↓ ER | [127] |
| Compound/Format                  | Effective Concentrations | Algal Source        | Experimental Model                                                                 | Inflammatory Phase | Significant Findings                      | Reference |
|---------------------------------|--------------------------|---------------------|------------------------------------------------------------------------------------|-------------------|-------------------------------------------|-----------|
| phlorotannins-rich ethanolic extract | 100, 200, 400 mg/kg/day; 8 weeks | *Ecklonia cava*     | Male Sprague Dawley rats; Experimental periodontitis induced by placing a sterile 4-0 silk ligature around the gingival cervix of the right mandibular second molar teeth | 1,2               | ↓ COX-2 activity ↓ PGE2 ↓ NO ↓ iNOS       | [130]     |
| Ethanolic extract and PPB       | ECE: 70 mg/kg PPB: 2.5 mg/kg; 4 weeks | *Ecklonia cava*     | Male C57BL/6N mice; HFD+/− seaweed supplement                                         | 1,2,3             | ↓ MCP-1 ↓ TNF-α ↓ IL-6 ↓ IL-10 ↓ iNOS ↓ CD80 ↑ CD206 ↓ ER stress ↓ size of white adipocytes ↑ PPAR expression | [138]     |
| Compound/Format | Effective Concentrations | Algal Source | Experimental Model | Inflammatory Phase 1 | Significant Findings 2 | Reference |
|----------------|--------------------------|--------------|-------------------|----------------------|------------------------|-----------|
| baicalein, luteolin, rosmarinic acid and cis-2-decenoic acid (10-HAD) | Test diet for mice: baicalein (650 mg/kg diet), luteolin (300 mg/kg diet), rosmarinic acid (500 mg/kg diet), 10-HAD (500 mg/kg diet); 4 weeks | Unknown | C3H/HeN inbred female mice; LD infection +/− test diet | Adult human; with a history of acute LD | Animal study: ↓ IL-6 ↓ TNF-α ↓ INF-γ Human study: By administration of the composition, 17.7% had slight physical and psychological improvement, and 17.7% were none responsive ↓ IL-17 | [139] |
| commercial (30%) polyphenolic fraction (VNP) Oral admin | Rat: 1 dose 2000 mg/kg 8 weeks | Sargassum fusiformi, Ecklonia kurome, Ecklonia Stolonifera, Eisenia bicyclis and Ecklonia cava | Sprague Dawley rat human (men) | Rat: serum ferric reducing antioxidant power (FRAP) significantly elevated 30 min after treatment, but declined quickly thereafter Human: ↑ erectile function (significantly) = usefulness of these polyphenolic compounds as chemo preventive agents against vascular risk factors originating from oxidative stress | [132] |
| Compound/Format                     | Effective Concentrations | Algal Source                                           | Experimental Model                  | Inflammatory Phase | Significant Findings                                                                 | Reference |
|-----------------------------------|--------------------------|--------------------------------------------------------|------------------------------------|--------------------|--------------------------------------------------------------------------------------|-----------|
| Compound 21                       | 35 mg/kg; 7 days         | Synthesized by the department of pharmaceutical chemistry | Female Lewis rats; MBP-induced EAE | 3                  | Attenuates neurological deficits, immune infiltration and demyelination in EAE rats  | [142]     |
|                                   |                          |                                                        |                                    |                    | Reduces the population of Th1/Th17 cells and inhibits their infiltration into the CNS |           |
| phloroglucinol derivative         | 1, 5, 10, 20, 50 mg/kg; 4 weeks | Unknown                                                | Cuprizone induced intoxication in mice, | 3                  | significantly improved neurological dysfunction and motor coordination impairment decreased microglia and astrocytes activities and the subsequent neuro-inflammatory response | [141]     |
| Compound 21                       |                          |                                                        |                                    |                    |                                                                                      |           |
| EtOAc Fraction of seaweed Crude Extract | 200 mg/kg; 8 weeks      | Ecklonia cava from Jeju or Gijang                    | C57BL/6 mice; HFD+/− seaweed supplement | 1,3                | ↓ TNF-a mRNA levels ↓ IL-16 mRNA levels ↓ body weights ↓ weight gain ↓ fat tissue mass ↓ Plasma ALT and cholesterol levels ↑ PPARγ2 mRNA expression ↑ C/EBPα, mRNA ↓ Blood glucose levels | [140]     |

1 Phases of inflammation as indicated in Table 1: 1-initiation of inflammation; 2-short term amplification and regulation; 3-short- or long-term consequences; 2 Symbols used: ↑—increase; ↓—decrease; =—no change.
**Appendix E**

**Table A5.** Effects of oral supplementation of brown seaweed derived Fucoxanthin(ol) and Meroterpenoid on inflammation-related parameters.

| Compound/Format | Effective Concentrations | Algal Source | Experimental Model | Inflammatory Phase | Significant Findings | Reference |
|------------------|--------------------------|--------------|--------------------|--------------------|----------------------|-----------|
| Fucoxanthin-containing extract | 13, 26 and 65 mg/kg Fx for 4 weeks | *Laminaria japonica* | Male Sprague Dawley rats (5 weeks old; ±200 g), diabetes induced by i.p. administration of streptozotocin followed by nicotinamide | 1,3 | ↓ TNF-α mRNA expression in plasma and testis | [150] |
| | | | | | ↓ IL-6 mRNA expression in plasma and testis | |
| | | | | | ↑ CAT, SOD and GPx activity in plasma | |
| | | | | | ↑ SOD activity in testis | |
| | | | | | ↓ H2O2 and O2− levels | |
| | | | | | ↓ MDA level in plasma, testis and sperm | |
| | | | | | ↓ Plasma glucose level | |
| | | | | | ↓ Insulin level | |
| | | | | | ↓ HOMA-IR | |
| | | | | | ↓ SOCS-3 mRNA expression in hypothalamus | |
| Fucoxanthin-rich brown algae extract | Colitis: 1, 2 or 5 g/kg bw/day for 7 days; CACC: 0.5, 1 or 2.5 g/kg bw/day for 11 weeks | *Sargassum muticum* | Male BALB/c mice (6–8 weeks old), 3% DSS-induced colitis for 14 days or CACC induction by a single i.p. injection of azoxymethane + 2% DSS for 7 consecutive days at weeks 3, 6 and 9 | 1,2 | ↓ TNF-α in colonic tissue and plasma | [151] |
| | | | | | ↓ IL-6 in plasma | |
| | | | | | =IL-6 in colonic tissue | |
| | | | | | ↓ Total NO content in colonic tissue | |
| | | | | | ↓ NO release in colonic tissue | |
| | | | | | ↓ MDA level in colonic tissue=MDA level in plasma | |
| | | | | | ↑ SOD levels in plasma | |
| | | | | | ↓ TNF-α in colonic tissue | |
| | | | | | ↓ IL-6 in colonic tissue | |
| | | | | | ↑ proliferation T and B cells | |
| | | | | | ↓ Total NO content in colonic tissue | |
| | | | | | ↓ NO release in colonic tissue | |
Table A5. Cont.

| Compound/Format              | Effective Concentrations                                      | Algal Source                              | Experimental Model                                                                 | Inflammatory Phase | Significant Findings 2 | Reference |
|------------------------------|----------------------------------------------------------------|-------------------------------------------|-------------------------------------------------------------------------------------|-------------------|------------------------|-----------|
| Fucoxanthin-rich extract     | 100, 200 or 500 mg/kg Fx, dissolved in olive oil and administered for 5 days | *Sargassum glaucescens*                  | Male Syrian hamsters (7 weeks old; 80–90 g), Cisplatin induced testicular damage group with CP i.p. injection before Fx treatment | 1,2,3             | ↑ CAT and GPx activity in testis↑ SOD activity in plasma↓ MDA level in testicular tissue, sperm and plasma↓ NO levels=Body weight | [152]     |
| Fucoxanthin                 | 0.4% and 0.6% Fx for 5 weeks                                   | Unknown                                   | Kunming strain mice (20–22 g) fed regular chow or HFD for 9 weeks + 5 weeks with Fx added to diet | 1,2,3             | ↓ Mammary gland inflammation↓ MPO activity↓ IL-1β in the blood↓ TNF-α in the blood↓ MDA level↓ COX-2 and iNOS mRNA expression↓ Body weight gain | [155]     |
| Fucoxanthin-rich wakame lipids (WLs) | WLs with 1.06% Fx; WLs with 2.22% Fx, administered for 5 weeks | *Undaria pinnatifida*                    | Male C57BL/6j mice (8 weeks old), normal-fat or HFD for 10 weeks followed by normal-fat or HFD with Fx for 5 weeks | 2,3               | ↓ MCP-1 mRNA expression in WAT=TNF-alfa mRNA expression in WAT↓ Body weight gain↓ Food intake↓ WAT weight gain↓ LDL cholesterol↓ Plasma leptin↓ Plasma insulin↓ blood glucose↑ Leptin mRNA expression in WAT↑ ADRB3 mRNA expression in WAT↑ GLUT4 mRNA expression in skeletal muscle | [156]     |
| Fucoxanthin and fucoxanthinol | 150 nmol/mouse, before induction of ear swelling               | Unknown                                   | Male ICR-strain mice (4 weeks old), AA-, TPA- or OXA-induced ear swelling           | 1                 | ↓ Inflammation in mouse ear swelling↓ PLA2 and COX-2 enzymatic activities | [157]     |
Table A5. Cont.

| Compound/Format | Effective Concentrations | Algal Source | Experimental Model | Inflammatory Phase | Significant Findings | Reference |
|-----------------|--------------------------|--------------|--------------------|-------------------|----------------------|-----------|
| Lipid extracts containing fucoxanthin | 0.10% Fx, 1 g Fx/kg of diet for 27 days | *Undaria pinnatifida* | Male KK-Ay mice (3 weeks old), fed an experimental diet with or without Fx | 1,2,3 | ↓ TNF-α mRNA expression in WAT ↓ MCP-1 mRNA expression in WAT ↓ Blood glucose level ↑ Glucose intolerance | [145] |
| Meroterpenoid | 90 and 180 mg MES/kg BW for 10 weeks | *Sargassum serratifolium* | Male C57BL/6J mice (6-weeks old), HCD | 2 | ↓ MCP-1, KC concentration in serum ↓ COX-2, ICAM-1, VCAM-1, MMP-9, MCP-1, beta-actin expression in aortic tissues | [148] |
| Meroterpenoid | 60 and 120 mg MES/kg BW/day for 8 weeks | *Sargassum serratifolium* | Male C57BL/6J mice (7-weeks old), HFD-induced obesity | 2,3 | ↓ F4/80, MCP-1 expression in epididymal tissue ↓ Body, liver and epididymal issue weight ↓ ALT, AST ↓ TG, glucose, free fatty acid in plasma ↑ HDL cholesterol ↑ UCP-1, ADRB3 expression in subcutaneous fat | [158] |
| Fucoxanthin and fucoidan | 275 mg LMF and 275 mg HSFx in 1 capsule, 3 capsules twice daily for 12 weeks | Unknown | Patients with nonalcoholic fatty liver disease (20–75 y/o) | 3 | ↓ BMI ↓ ALT = liver steatosis (=CAP) = adiponectin = fasting insulin = insulin resistance | [159] |

1 Phases of inflammation as indicated in Table 1: 1-initiation of inflammation; 2-short term amplification and regulation; 3-short- or long-term consequences; 2 Symbols used: ↑—increase; ↓—decrease; =—no change.
References

1. Cherry, P.; O’Hara, C.; Magee, P.; McSorley, E.M.; Allsopp, P.J. Risks and benefits of consuming edible seaweeds. *Nutr. Rev.* 2019, 77, 307–329. [CrossRef] [PubMed]

2. Bramer, W.; Milic, J.; Mast, F. Reviewing retrieved references for inclusion in systematic reviews using EndNote. *J. Med. Libr. Assoc.* 2017, 105, 84–87. [CrossRef]

3. Jeong, D.-H.; Kim, K.-B.; Kim, M.-J.; Kang, B.-K.; Ahn, D.-H. Anti-inflammatory activity of ethanolic extract of *Sargassum micracanthum*. *J. Microbiol. Biotechnol.* 2013, 23, 1691–1698. [CrossRef]

4. Güner, A.; Köksal, C.; Erel, B.; Kayalar, H.; Nalbantsoy, A.; Sukatar, A.; Yavaşoğlu, N.K. Antimicrobial and antioxidant activities with acute toxicity, cytotoxicity and mutagenicity of *Cystoseira compressa* (Esper) Gerloff & Nizamuddin from the coast of Urla (Izmir, Turkey). *Cytotechnology* 2013, 67, 135–143. [CrossRef] [PubMed]

5. Zaragozá, M.C.; López, D.; Sáiz, M.P.; Poquet, M.; Pérez, J.; Puig-Parellada, P.; Mármol, F.; Simonetti, P.; Gardana, C.; Lerat, Y.; et al. Toxicity and Antioxidant Activity in vitro and in Vivo of Two Fucus vesiculosus Extracts. *J. Agric. Food Chem.* 2008, 56, 7773–7780. [CrossRef] [PubMed]

6. Park, S.Y.; Seo, I.S.; Lee, S.J.; Lee, S.P. Study on the Health Benefits of Brown Algae (*Sargassum muticum*) in Volunteers. *J. Food Nutr. Res.* 2015, 3, 126–130. [CrossRef]

7. Baldrick, F.R.; McFadden, K.; Ibars, M.; Sung, C.; Moffatt, T.; Megarry, K.; Thomas, K.; Mitchell, P.; Wallace, J.M.W.; Pourshahidi, M.C.; Línez, M.P.; Poquet, M.; Puech, J.; Puig-Parellada, P.; Mato, M.; Hanaoka, K.-I.; Miyata, M. Suppressive activity of a (poly)phenol-rich extract from the brown algae *Sargassum ilicifolium* on lipopolysaccharide-stimulated mouse peritoneal macrophages and identification of active components. *Skin Pharmacol. Physiol.* 2018, 31, 212–219. [CrossRef]

8. Kannan, G.; Saker, K.; Terrill, T.; Koukoul, B.; Galipalli, S.; Gelaye, S. Effect of seaweed extract supplementation in goats exposed to simulated slaughter stress. *Small Rumin. Res.* 2007, 73, 221–227. [CrossRef]

9. Bai, J.; Wang, R.; Yan, L.; Feng, J. Co-Supplementation of Dietary Seaweed Powder and Antibacterial Peptides Improves Broiler Growth Performance and Immune Function. *J. Poult. Sci.* 2019, 21. [CrossRef]

10. Baleta, F.N.; Bolanos, J.M. Growth and immune response of *Pangasius hypophthalmus* fed diets containing seaweed extracts as immunostimulant. *Braz. Arch. Biol. Technol.* 2019, 62. [CrossRef]

11. Zeynali, M.; Bahabadi, M.N.; Morshedi, V.; Ghasemi, A.; Mozanzadeh, M.T. Replacement of dietary fishmeal with *Hizikia fusiforme* in a mouse model in vitro and ex vivo. *Mar. Biotechnol.* 2017, 19, 65–75. [CrossRef]

12. Sugiura, Y.; Kinoshita, Y.; Abe, M.; Murase, N.; Tanaka, R.; Matsuishita, T.; Usui, M.; Hanaoka, K.-I.; Miyata, M. Suppressive effects of the diethyl ether fraction from a brown alga *Sargassum fusiforme* on allergic and inflammatory reactions. *Fish. Sci.* 2016, 82, 369–377. [CrossRef]

13. Namkoong, S.; Kang, S.-C.; Do, H.; Jang, K.-H.; Jang, S.-A.; Choong, M.-G.; Sohn, E.-H. Immunomodulatory Effects of Supplemental with Extracts from the Marine Brown Alga *Eisenia bicyclis* on Macrophages. *Korean J. Plant Resour.* 2011, 24, 298–303. [CrossRef]

14. Sugiyama, Y.; Matsuda, K.; Okamoto, T.; Kakinuma, M.; Amano, H. Anti-allergic effects of the brown alga *Eisenia arborea* on Brown Norwegian rats. *Fish. Sci.* 2008, 74, 180–186. [CrossRef]

15. Yoshioka, H.; Ishida, M.; Nishi, K.; Oda, H.; Toyohara, H.; Sugahara, T. Studies on anti-allergic activity of *Sargassum horneri* extract. *J. Funct. Foods* 2010, 14, 154–160. [CrossRef]

16. Han, E.J.; Fernando, I.P.S.; Kim, H.-S.; Jeon, Y.-J.; Madusanka, D.M.D.; Dias, M.K.H.M.; Lee, Y.; Ahn, G. Oral Administration of *Sargassum horneri* Improves the HDM/DNCD-Induced Atopic Dermatitis in NC/Nga Mice and Inflamed HaCaT Keratinocytes via the Downregulation of STAT1. *Nutrients* 2015, 7773–7780. [CrossRef] [PubMed]

17. Han, E.J.; Fernando, I.P.S.; Kim, H.-S.; Jeon, Y.-J.; Madusanka, D.M.D.; Dias, M.K.H.M.; Lee, Y.; Ahn, G. Oral Administration of *Sargassum horneri* Improves the HDM/DNCD-Induced Atopic Dermatitis in NC/Nga Mice. *Nutr. Res.* 2015, 35, 626–636. [CrossRef]

18. Yoshihara, K.; Saito, S.; Saito, Y.; Uemura, M.; Ueda, Y.; Ishimura, K.; Kinoshita, Y.; Abe, M.; Murase, N.; Tanaka, R. Matsuishita, T.; Usui, M.; Hanaoka, K.-I.; Miyata, M. Suppressive effects of the diethyl ether fraction from a brown alga *Sargassum fusiforme* on allergic and inflammatory reactions. *Fish. Sci.* 2016, 82, 369–377. [CrossRef]

19. Namkoong, S.; Kang, S.-C.; Do, H.; Jang, K.-H.; Jang, S.-A.; Choong, M.-G.; Sohn, E.-H. Immunomodulatory Effects of Supplemental with Extracts from the Marine Brown Alga *Eisenia bicyclis* on Macrophages. *Korean J. Plant Resour.* 2011, 24, 298–303. [CrossRef]

20. Park, S.Y.; Hwang, E.; Shin, Y.-K.; Lee, D.-G.; Yang, J.-E.; Park, J.-H.; Yi, T.-H. Immunostimulatory effect of enzyme-modified *Hizikia fusiforme* in a mouse model in vitro and ex vivo. *Mar. Biotechnol.* 2017, 19, 65–75. [CrossRef]

21. Park, S.Y.; Hwang, E.; Shin, Y.-K.; Lee, D.-G.; Yang, J.-E.; Park, J.-H.; Yi, T.-H. Immunostimulatory effect of enzyme-modified *Hizikia fusiforme* in a mouse model in vitro and ex vivo. *Mar. Biotechnol.* 2017, 19, 65–75. [CrossRef]

22. Jeong, D.-H.; Kim, K.-B.; Kim, M.-J.; Kang, B.-K.; Ahn, D.-H. Anti-inflammatory activity of ethanolic extract of *Sargassum micracanthum*. *J. Microbiol. Biotechnol.* 2013, 23, 1691–1698. [CrossRef]
24. Fernando, I.P.S.; Sanjeeva, K.K.A.; Samarakoon, K.W.; Lee, W.W.; Kim, H.-S.; Ranasinghe, P.; Gunasekara, U.K.D.S.S.; Jeon, Y.-J. Antioxidant and anti-inflammatory functionality of ten Sri Lankan seaweed extracts obtained by carbohydrate assisted extraction. *Food Sci. Biotechnol.* 2018, 27, 1761–1769. [CrossRef] [PubMed]

25. Ramadan, G.; Fouda, W.A.; Ellamie, A.M.; Ibrahim, W.M. Dietary supplementation of *Sargassum latifolium* modulates thermoregulatory response, inflammation, and oxidative stress in bacterial endotoxin-challenged male Barki sheep. *Environ. Sci. Pollut. Res.* 2020, 27, 33863–33871. [CrossRef] [PubMed]

26. Ellamie, A.M.; Fouda, W.A.; Ibrahim, W.M.; Ramadan, G. Dietary supplementation of brown seaweed (*Sargassum latifolium*) alleviates the environmental heat stress-induced toxicity in male Barki sheep (*Ovis aries*). *J. Therm. Biol.* 2020, 89, 102561. [CrossRef]

27. Saker, K.E.; Fike, J.H.; Veit, H.; Ward, D.L. Brown seaweed- (TascoTM) treated conserved forage enhances antioxidant status and immune function in heat-stressed wether lambs. *J. Anim. Physiol. Anim. Nutr.* 2004, 88, 122–130. [CrossRef] [PubMed]

28. Ko, S.J.; Bu, Y.; Bae, J.; Bang, Y.-m.; Kim, J.; Lee, H.; Lee, B.-J.; Hyun, Y.H.; Park, J.-W. Protective effect of Laminaria japonica with probiotics on murine colitis. *Mediat. Inflamm.* 2014, 2014, 417814. [CrossRef]

29. Yang, H.; Lee, Y.-J.; Ham, Y.-M.; Yoon, S.-A.; Kang, S.C. Anti-Arthritis Effect through the Anti-Inflammatory Effect of *Sargassum muticum* Extract in Collagen-Induced Arthritis (CIA) Mice. *Molecules* 2019, 24, 276. [CrossRef]

30. Cooper, R.; Dragar, C.; Elliot, K.; Fitton, J.; Godwin, J.; Thompson, K. GFS, a preparation of Tasmanian *Palmaria palmata* Algae, Exerts Metabolic Benefits in Diet-Induced Obesity in Mice. *Nutr. Res. Pract.* 2016, 10, 42–48. [CrossRef] [PubMed]

31. Martinez-Villaluenga, C.; Peñas, E.; Rico, D.; Martín-Diana, A.B.; Portillo, M.P.; Macarulla, M.T.; De Luis, D.A.; Miranda, J. Potential Usefulness of a Wakame/Carob Functional Snack for the Treatment of Several Aspects of Metabolic Syndrome: From In Vitro to In Vivo Studies. *Mar. Drugs* 2018, 16, 512. [CrossRef] [PubMed]

32. Van Weelden, G.; Bobinski, M.; Okia, K.; van Weelden, W.J.; Romano, A.; Pijnenborg, A.M.A. Fucoidan Structure and Activity in Brown Seaweeds—An overview of enzymes active toward this class of polysaccharide. *Glycobiology* 2003, 13, 29R–40R. [CrossRef]

33. Kraan, S. Alleviation of osteoarthritis and alveolar bone loss in collagen-induced arthritis (CIA) mice by *Undaria pinnatifida* complex polysaccharide. *Molecules* 2019, 24, 2340. [CrossRef] [PubMed]

34. Jeon, H.; Yoon, W.-J.; Ham, Y.-M.; Yoon, S.-A.; Kang, S.C. Anti-Arthritis Effect through the Anti-Inflammatory Effect of *Sargassum muticum* Extract in Collagen-Induced Arthritis (CIA) Mice. *Molecules* 2019, 24, 276. [CrossRef]

35. Berteau, O.; Stringer, D.N.; Karpiniec, S.S. Therapies from Fucoidan: An Update. *Mar. Drugs* 2018, 16, 211. [CrossRef] [PubMed]

36. Martínez-Villaluenga, C.; Peñas, E.; Rico, D.; Martín-Diana, A.B.; Portillo, M.P.; Macarulla, M.T.; De Luis, D.A.; Miranda, J. Protective Effect of Hiziki Extracts on the Progression of Periodontitis. *Mar. Biotechnol.* 2018, 20, 313–323. [CrossRef] [PubMed]

37. Martinez-Villaluenga, C.; Peñas, E.; Rico, D.; Martin-Diana, A.B.; Portillo, M.P.; Macarulla, M.T.; De Luis, D.A.; Miranda, J. Protective Effect of Hiziki Extracts on the Progression of Periodontitis. *Mar. Biotechnol.* 2018, 20, 313–323. [CrossRef] [PubMed]

38. Mendez, R.L.; Miranda, C.; Armour, C.R.; Sharpton, T.J.; Stevens, J.F.; Kwon, J.Y. Supplementation with Sea Vegetables Exerts Metabolic Benefits in Diet-Induced Obesity in Mice. *Curr. Dev. Nutr.* 2020, 4, nzaa072. [CrossRef] [PubMed]

39. Holdt, S.L.; Kraan, S. Bioactive compounds in seaweed: Functional food applications and legislation. *Environ. Boil. Fishes* 2011, 23, 543–597. [CrossRef] [PubMed]

40. Van Weelden, G.; Bobinski, M.; Okia, K.; van Weelden, W.J.; Romano, A.; Pijnenborg, A.M.A. Fucoidan Structure and Activity in Relation to Anti-Cancer Mechanisms. *Mar. Drugs* 2019, 17, 32. [CrossRef] [PubMed]

41. Laurienzo, P. Marine Polysaccharides in Pharmaceutical Applications: An Overview. *Mar. Drugs* 2010, 8, 2435–2465. [CrossRef]

42. Zhao, X.; Xue, C.-H.; Li, B.-F. Study of antioxidant activities of sulfated polysaccharides from *Laminaria japonica*. *J. Appl. Phycol.* 2007, 20, 431–436. [CrossRef]

43. Fitton, J.H.; Stringer, D.N.; Karpiniec, S.S. Therapies from Fucoidan: An Update. *Mar. Drugs* 2015, 13, 5920–5946. [CrossRef] [PubMed]

44. Namamine, T.; Nakazato, K.; Tomioka, S.; Iha, M.; Nakajima, K. Intestinal Absorption of Fucoidan Extracted from the Brown Seaweed, *Cladosiphon okamuratus*. *Mar. Drugs* 2014, 13, 48–64. [CrossRef]

45. Shang, Q.; Song, G.; Zhang, M.; Shi, J.; Xu, C.; Hao, J.; Li, G.; Yu, G. Dietary fucoidan improves metabolic syndrome in association with increased *Akkermansia* population in the gut microbiota of high-fat diet-fed mice. *J. Funct. Foods* 2017, 28, 138–146. [CrossRef] [PubMed]

46. Kadena, K.; Tomori, M.; Iha, M.; Namamine, T. Absorption Study of Mozuku Fucoidan in Japanese Volunteers. *Mar. Drugs* 2018, 16, 254. [CrossRef]

47. Iraha, A. Fucoidan enhances intestinal barrier function by upregulating the expression of claudin-1. *World J. Gastroenterol.* 2013, 19, 5500–5507. [CrossRef]

48. Chauviere, C.; Aïd-Launais, R.; Aerts, J.; Chaubet, F.; Maire, M.; Chollet, L.; Rolland, L.; Bonafé, R.; Rossi, S.; Bussi, S.; et al. Pharmaceutical Development and Safety Evaluation of a GMP-Grade Fucoidan for Molecular Diagnosis of Cardiovascular Diseases. *Mar. Drugs* 2019, 17, 699. [CrossRef]
51. Li, N.; Zhang, Q.; Song, J. Toxicological evaluation of fucoidan extracted from Laminaria japonica in Wistar rats. Food Chem. Toxicol. 2005, 43, 421–426. [CrossRef] [PubMed]

52. Mori, N.; Takeda, K.; Tomimori, K.; Kimura, R.; Ishikawa, C.; Nowling, T.K. Anti-tumor activity of fucoidan is mediated by nitric oxide released from macrophages. Int. J. Oncol. 2011, 40, 251–260. [CrossRef]

53. Jayawardena, T.U.; Fernando, I.P.; Lee, W.W.; Sanjeewa, K.K.A.; Kim, H.-S.; Lee, D.-S.; Jeon, Y.-J. Isolation and purification of fucoidan from Turbinaria ornata from the Maldives; Inflammation inhibitory potential under LPS stimulated conditions in in-vitro and in-vivo models. Int. J. Biol. Macromol. 2019, 131, 614–623. [CrossRef] [PubMed]

54. Ni, L.; Wang, L.; Fu, X.; Duan, D.; Jeon, Y.-J.; Xu, J.; Gao, X. In vitro and in vivo anti-inflammatory activities of a fucose-rich fucoidan isolated from Saccharina japonica. Int. J. Biol. Macromol. 2020, 156, 717–729. [CrossRef]

55. Park, J.; Cha, J.-D.; Choi, K.-M.; Lee, K.-Y.; Han, K.M.; Jang, Y.-S. Fucoidan inhibits LPS-induced inflammation in vitro and during the acute response in vivo. Int. Immunopharmacol. 2017, 43, 91–98. [CrossRef]

56. Sanjeeva, K.K.A.; Fernando, I.; Kim, S.-Y.; Kim, H.-S.; Ahn, G.; Jee, Y.; Jeon, Y.-J. In vitro and in vivo anti-inflammatory activities of high molecular weight sulfated polysaccharide; containing fucose separated from Sargassum horneri: Short communication. Int. J. Biol. Macromol. 2018, 107, 803–807. [CrossRef] [PubMed]

57. Herath, K.H.I.N.M.; Kim, H.J.; Kim, A.; Sook, C.E.; Lee, B.-Y.; Jee, Y. The Role of Fucoidans Isolated from the Sporophylls of Undaria pinnatifida against Particulate-Matter-Induced Allergic Airway Inflammation: Evidence of the Attenuation of Oxidative Stress and Inflammatory Responses. Molecules 2020, 25, 2869. [CrossRef]

58. Lin, R.; Liu, X.; Meng, Y.; Xu, M.; Guo, J. Effects of Laminaria japonica polysaccharides on airway inflammation of lungs in an asthma mouse model. Multidisciip. Respir. Med. 2015, 10, 20. [CrossRef] [PubMed]

59. Tanino, Y.; Hashimoto, T.; Ojima, T.; Mizuno, M. F-fucoidan from Saccharina japonica is a novel inducer of galectin-9 and exhibits anti-allergic activity. J. Clin. Biochem. Nutr. 2016, 59, 25–30. [CrossRef]

60. Mizuno, M.; Sakaguchi, K.; Sakane, I. Oral Administration of Fucoidan Can Exert Anti-Allergic Activity after Allergen Sensitization by Enhancement of Galectin-9 Secretion in Blood. Biomolecules 2020, 10, 258. [CrossRef]

61. Hwang, P.-A.; Lin, H.-Y.; Lin, H.-Y.; Lo, S.-K. Dietary Supplementation with Low-Molecular-Weight Fucoidan Enhances Innate and Adaptive Immune Responses and Protects against Mycoplasma pneumoniae Antigen Stimulation. Mar. Drugs 2019, 17, 175. [CrossRef] [PubMed]

62. Tomori, M.; Nagamine, T.; Miyamoto, T.; Iha, M. Evaluation of the Immunomodulatory Effects of Fucoidan Derived from Cladosiphon Okamuranus Tokida in Mice. Mar. Drugs 2019, 17, 547. [CrossRef]

63. Yu, B.; Bi, D.; Yao, L.; Li, T.; Gu, L.; Xu, H.; Li, X.; Li, H.; Hu, Z.-L.; Xu, X. The inhibitory activity of alginate against allergic reactions in an ovalbumin-induced mouse model. Food Funct. 2020, 11, 2704–2713. [CrossRef] [PubMed]

64. Leonard, S.G.; Sweeney, T.; Bahar, B.; O’Doherty, J.V. Effect of maternal seaweed extract supplementation on suckling piglet growth, humoral immunity, selected microflora, and immune response after an ex vivo lipopolysaccharide challenge. J. Anim. Sci. 2012, 90, 505–514. [CrossRef]

65. Walsh, A.M.; Sweeney, T.; O’Shea, C.J.; Doyle, D.N.; O’Doherty, J.V. Effects of supplementing dietary laminarin and fucoidan on intestinal morphology and the immune gene expression in the weaned pig. J. Anim. Sci. 2012, 90, 284–286. [CrossRef]

66. Azizi, A.F.N.; Miyazaki, R.; Yumito, T.; Ohashi, Y.; Uno, S.; Miyajima, U.; Kumamoto, M.; Uchiyama, S.; Yasuda, M. Effect of maternal supplementation with seaweed powder on immune status of liver and lymphoid organs of piglets. J. Vet. Med. Sci. 2018, 80, 8–12. [CrossRef] [PubMed]

67. Heim, G.; O’Doherty, J.V.; O’Shea, C.; Doyle, D.N.; Egan, A.M.; Thornton, K.; Sweeney, T. Maternal supplementation of seaweed-derived polysaccharides improves intestinal health and immune status of suckling piglets. J. Nutr. Sci. 2015, 4, e27. [CrossRef] [PubMed]

68. McDonnell, R.P.; Doherty, J.V.O.; Earley, B.; Clarke, A.M.; Kenny, D.A. Effect of supplementation with n-3 polyunsaturated fatty acids and/or β-glucans on performance, feeding behaviour and immune status of Holstein Friesian bull calves during the pre- and post-weaning periods. J. Anim. Sci. Biotechnol. 2019, 10, 1–17. [CrossRef]

69. Yan, G.L.; Guo, Y.M.; Yuan, J.M.; Liu, D.; Zhang, B.K. Sodium alginate oligosaccharides from brown algae inhibit Salmonella Enteritidis colonization in broiler chickens. Poult. Sci. 2011, 90, 1441–1448. [CrossRef] [PubMed]

70. El-Boshy, M.; El-Ashtam, A.; Risha, E.; Abdelhamid, F.; Zahran, E.; Gab-Alla, A. Dietary fucoidan enhance the non-specific immune response and disease resistance in African catfish, Clarias gariepinus, immunosuppressed by cadmium chloride. Vet. Immunol. Immunopathol. 2014, 162, 168–173. [CrossRef]

71. Mir, I.N.; Sahu, N.P.; Pal, A.K.; Makesh, M. Synergistic effect of l-methionine and fucoidan rich extract in eliciting growth and non-specific immune re-sponse of Labro rohita fingerlings against Aeromonas hydrophila. Aquaculture 2017, 479, 396–403. [CrossRef]

72. Morales-Lange, B.; Benthke, J.; Schmitt, P.; Mercado, L. Phenotypical parameters as a tool to evaluate the immunostimulatory effects of laminarin in Oncorhynchus mykiss. Aquac. Res. 2014, 46, 2707–2715. [CrossRef]

73. Prabu, D.L.; Sahu, N.P.; Pal, A.K.; Dasgupta, S.; Narendra, A. Immunomodulation and interferon gamma gene expression in sutchi cat fish, Pangasianodon hypophthalmus: Effect of dietary fucoidan rich seaweed extract (FRESE) on pre and post challenge period. Aquac. Res. 2016, 47, 199–218. [CrossRef]

74. Setyawaran, A.; Isanasetyo, A.; Murwantoko, M.; Soedarmanto, I.; Handayani, C.R. Comparative immune response of dietary fucoidan from three indonesian brown algaes in white shrimp Litopenaeus vannamei. AACL Bioflux 2018, 11, 1707–1723.
75. Yang, Q.; Yang, R.; Li, M.; Zhou, Q.; Liang, X.; Elmada, Z.C. Effects of dietary fucoidan on the blood constituents, anti-oxidation and innate immunity of juvenile yellow catfish (Pelteobagrus fulvidraco). *Fish Shellfish Immunol.* 2014, 41, 264–270. [CrossRef] [PubMed]

76. Yin, C.; Li, W.; Lin, Q.; Lin, X.; Lin, J.; Zhu, Q.; Jiang, H.; Huang, Z. Dietary administration of laminarin improves the growth performance and immune responses in *Epinephelus coioides*. *Fish Shellfish Immunol.* 2014, 41, 402–406. [CrossRef]

77. Katayama, S.; Nishio, T.; Kishimura, H.; Saeki, H. Immunomodulatory Properties of Highly Viscous Polysaccharide Extract from the Gagole Algae (*Kjellmaniella crassifolia*). *Plant Foods Hum. Nutr.* 2012, 67, 76–81. [CrossRef] [PubMed]

78. Shimizu, J.; Wada-Funada, U.; Mano, H.; Matahira, Y.; Kawaguchi, M.; Wada, M. Proportion of Murine Cytotoxic T Cells is Increased by High Molecular-Weight Fucoidan Extracted from *Okinawa mozuku* (*Cladosiphon okamuranus*). *J. Health Sci.* 2005, 51, 394–397. [CrossRef]

79. Kar, S.; Sharma, G.; Das, P.K. Fucoidan cures infection with both antimony-susceptible and -resistant strains of *Leishmania donovani* through Th1 response and macrophage-derived oxidants. *J. Antimicrob. Chemother.* 2011, 66, 618–625. [CrossRef]

80. Hayashi, T.; Hayashi, K.; Kanekiyo, K.; Ohta, Y.; Lee, J.-B.; Hashimoto, M.; Nakano, T. Promising Antiviral Glyco-Molecules from an Edible Algae. In *Combating the Threat of Pandemic Influenza: Drug Discovery Approaches*; John Wiley & Sons: Hoboken, NJ, USA, 2007; pp. 166–182. [CrossRef]

81. Araya, N.; Takahashi, K.; Sato, T.; Nakamura, T.; Sawa, C.; Hasegawa, D.; Ando, H.; Aratani, S.; Yagishita, N.; Fuji, R.; et al. Fucoidan therapy decreases the proviral load in patients with human T-lymphotropic virus type-I-associated neurological disease. *Antivir. Ther.* 2011, 16, 89–98. [CrossRef]

82. Hayashi, K.; Nakano, T.; Hashimoto, M.; Kanekiyo, K.; Hayashi, T. Defensive effects of a fucoidan from brown alga *Undaria pinnatifida* against herpes simplex virus infection. *Int. Immunopharmacol.* 2008, 8, 109–116. [CrossRef] [PubMed]

83. Hayashi, K.; Lee, J.-B.; Nakano, T.; Hayashi, T. Anti-influenza A virus characteristics of a fucoidan from sporophyll of *Undaria pinnatifida* in mice with normal and compromised immunity. *Microbes Infect.* 2013, 15, 302–309. [CrossRef] [PubMed]

84. Maruyama, H.; Tamauchi, H.; Iizuka, M.; Nakano, T. The Role of NK cells in Antitumor Activity of Dietary Fucoidan from *Undaria pinnatifida* Sporophylls (Mekabu). *Planta Med.* 2006, 72, 1415–1417. [CrossRef] [PubMed]

85. Azuma, K.; Ishihara, T.; Nakamoto, H.; Amaha, T.; Osaki, T.; Tsuka, T.; Imagawa, T.; Minami, S.; Takashima, O.; Ifuku, S.; et al. Effects of Oral Administration of Fucoidan Extracted from *Cladosiphon okamuranus* on Tumor Growth and Survival Time in a Tumor-Bearing Mouse Model. *Mar. Drugs* 2012, 10, 2377–2348. [CrossRef] [PubMed]

86. Fan, S.; Zhang, J.; Nie, W.; Zhou, W.; Jin, L.; Chen, X.; Lu, J. Antitumor effects of polysaccharide from *Sargassum fusiforme* against human hepatocellular carcinoma HepG2 cells. *Food Chem. Toxicol.* 2017, 102, 53–62. [CrossRef]

87. Chen, X.; Nie, W.; Yu, G.; Li, Y.; Hu, Y.; Lu, J.; Jin, L. Antitumor and immunomodulatory activity of polysaccharides from *Sargassum fusiforme*. *Food Chem. Toxicol.* 2012, 50, 695–700. [CrossRef]

88. Fan, S.; Yu, G.; Nie, W.; Jin, J.; Chen, L.; Chen, X. Antitumor activity and underlying mechanism of *Sargassum fusiforme* polysaccharides in CNE-bearing mice. *Int. J. Biol. Macromol.* 2018, 112, 516–522. [CrossRef]

89. Atashrazm, F.; Lowenthal, R.M.; Woods, G.; Holloway, A.; Karpiniec, S.S.; Dickinson, J.L. Fucoidan Suppresses the Growth of Human Acute Promyelocytic Leukemia Cells In Vitro and In Vivo. *J. Cell. Physiol.* 2015, 231, 688–697. [CrossRef]

90. Xue, M.; Liang, H.; Tang, Q.; Xue, C.; He, X.; Zhang, L.; Zhang, Z.; Liang, Z.; Bian, K.; Zhang, L.; et al. The Protective and Immunomodulatory Effects of Fucoidan Against 7,12-Dimethyl benz[a]anthracene-Induced Experimental Mammary Carcinogenesis Through the PDI/PLDI Signaling Pathway in Rats. *Nutr. Cancer* 2017, 69, 1234–1244. [CrossRef]

91. Jiang, Z.; Abu, R.; Isaka, S.; Nakazono, S.; Ueno, M.; Okimura, T.; Yamaguchi, K.; Oda, T. Inhibitory effect of orally-administered sulfated polysaccharide ascophyllan isolated from *ascophyllum nodosum* on the growth of sarcoma-180 solid tumor in mice. *Anticancer Res.* 2014, 34, 1663–1671. [PubMed]

92. Chen, X.; Nie, W.; Fan, S.; Zhang, J.; Wang, Y.; Lu, J.; Jin, L. A polysaccharide from *Sargassum fusiforme* protects against immunosuppression in cyclophosphamide-treated mice. *Carbohydr. Polym.* 2012, 90, 1114–1119. [CrossRef]

93. Lee, H.H.; Cho, Y.; Kim, G.-H.; Cho, H. *Undaria pinnatifida* Fucoidan-Rich Extract Recovers Immunity of Immunosuppressed Mice. *J. Microbiol. Biotechnol.* 2020, 30, 439–447. [CrossRef]

94. Zhu, X.; Zhu, R.; Jian, Z.; Yu, H. Laminarin enhances the activity of natural killer cells in immunosuppressed mice. *Cent. Eur. J. Immunol.* 2019, 44, 357–363. [CrossRef]

95. Hwang, P.-A.; Hung, Y.-L.; Chien, S.-Y. Inhibitory activity of *Sargassum hemiphyllum* sulfated polysaccharide in arachidonic acid-induced animal models of inflammation. *J. Food Drug Anal.* 2015, 23, 49–56. [CrossRef] [PubMed]

96. Kyung, J.; Kim, D.; Park, D.; Yang, Y.-H.; Choi, E.-K.; Lee, S.-P.; Kim, T.-S.; Lee, Y.-B.; Kim, Y.-B. Synergistic anti-inflammatory effects of *Laminaria japonica* fucoidan and Cistanche tubulosa extract. *Lab. Anim. Res.* 2012, 28, 91–97. [CrossRef]

97. Choi, J.-I.; Raghavendran, H.R.B.; Sung, N.-Y.; Kim, J.-H.; Chun, B.S.; Ahn, D.H.; Choi, H.-S.; Kang, K.-W.; Lee, J.-W. Effect of fucoidan on aspirin-induced stomach ulceration in rats. *Chem. Interact.* 2010, 183, 249–254. [CrossRef]

98. Matsumont, S.; Nagaoka, M.; Haru, T.; Kimura-Takagi, I.; Mistuyama, K.; Ueyama, S. Fucoidan derived from *Cladosiphon okamuranus* Tokida ameliorates murine chronic colitis through the down-regulation of interleukin-6 production on colonic epithelial cells. *Clin. Exp. Immunol.* 2004, 136, 432–439. [CrossRef]

99. Lean, Q.Y.; Eri, R.D.; Fitton, J.H.; Patel, R.P.; Gueven, N. Fucoidan Extracts Ameliorate Acute Colitis. *PLoS ONE* 2015, 10, e0128453. [CrossRef] [PubMed]
100. Wang, L.; Ai, C.; Wen, C.; Qin, Y.; Liu, Z.; Wang, L.; Gong, Y.; Su, C.; Wang, Z.; Song. Fucoidan isolated from *Ascophyllum nodosum* alleviates gut microbiota dysbiosis and colonic inflammation in antibiotic-treated mice. *Food Funct.* 2020, 11, 5595–5606. [CrossRef] [PubMed]

101. Xue, M.; Liang, H.; Ji, X.; Zhou, Z.; Liu, Y.; Sun, T.; Zhang, L. Effects of fucoidan on gut flora and tumor prevention in 1,2-dimethylhydrazine-induced colorectal carcino genesis. *J. Nutr. Biochem.* 2020, 82, 108396. [CrossRef]

102. Park, S.-B.; Chun, K.-R.; Kim, J.-K.; Suk, K.; Jung, Y.-M.; Lee, W.-H. The differential effect of high and low molecular weight fucoidans on the severity of collagen-induced arthritis in mice. *Plathyther. Res.* 2010, 24, 1384–1391. [CrossRef] [PubMed]

103. Jeong, J.-W.; Hwang, S.J.; Han, M.H.; Lee, D.-S.; Yoo, J.S.; Choi, I.-W.; Cha, H.-J.; Kim, S.; Kim, H.-S.; Kim, G.-Y.; et al. Fucoidan inhibits lipopolysaccharide-induced inflammatory responses in RAW 264.7 macrophages and zebrafish larvae. *Mol. Cell. Toxicol.* 2017, 13, 405–417. [CrossRef]

104. Yu, H.-H.; Chengchuan Ko, E.; Chang, C.-L.; Yuan, K.S.-P.; Wu, A.T.H.; Shan, Y.-S.; Wu, S.-Y. Fucoidan Inhibits Radiation-Induced Pneumonitis and Lung Fibrosis by Reducing Inflammatory Cytokine Expression in Lung Tissues. *Mar. Drugs* 2018, 16, 392. [CrossRef]

105. Bai, X.; Li, M.; Wang, X.; Chang, H.; Ni, Y.; Li, C.; He, K.; Wang, H.; Yang, Y.; Tian, T.; et al. Therapeutic potential of fucoidan in the reduction of hepatic pathology in murine *schistosomiasis japonica*. *Parasites Vectors* 2020, 13, 1–14. [CrossRef]

106. Li, J.; Chen, K.; Li, S.; Liu, T.; Wang, F.; Xia, Y.; Lu, J.; Zhou, Y.; Guo, C. Pretreatment with Fucoidan from *Fucus vesiculosus* Protected against ConA-Induced Acute Liver Injury by Inhibiting Both Intrinsic and Extrinsic Apoptosis. *PLoS ONE* 2016, 11, e0152570. [CrossRef] [PubMed]

107. Xue, M.; Liang, H.; Ji, X.; Liu, Y.; Hou, L.; Sun, T. Fucoidan prevent murine autoimmune diabetes via suppression TLR4-signaling pathways, regulation DC/Treg induced immune tolerance and improving gut microbiota. *Nutr. Metab.* 2019, 16, 1–15. [CrossRef]

108. Ko, W.-S.; Shen, F.-P.; Shih, C.-J.; Chiu, Y.-L. The 25(OH)Vitamin D Status Affected the Effectiveness of Oligo Fucoidan in Patients with Chronic Hepatitis B Virus Infection with Immune Tolerance Phase. *Nutrients* 2020, 12, 321. [CrossRef]

109. Jeong, J.-W.; Hwang, S.J.; Han, M.H.; Lee, D.-S.; Yoo, J.S.; Choi, I.-W.; Cha, H.-J.; Kim, S.; Kim, H.-S.; Kim, G.-Y.; et al. Fucoidan attenuates atherosclerosis in LDLR−/− mice through interfering the leukocyte-endothelial cells interaction. *Mol. Med. Rep.* 2018, 323. [CrossRef]

110. Yu, H.-H.; Chengchuan Ko, E.; Chang, C.-L.; Yuan, K.S.-P.; Wu, A.T.H.; Shan, Y.-S.; Wu, S.-Y. Fucoidan Inhibits Radiation-Induced Pneumonitis and Lung Fibrosis by Reducing Inflammatory Cytokine Expression in Lung Tissues. *Mar. Drugs* 2018, 16, 392. [CrossRef]

111. Soin, J.; Kurzejamska, E.; Gaciong, Z.; Henrykowska, G.; Bojakowski, K. Fucoidan Inhibits Vascular Remodeling in Transplant Aneurysm through Interfering the Leukocyte-endothelial Cells Interaction. *Mol. Med. Rep.* 2018, 17, 7089–7096. [CrossRef]

112. Mo, W.; Wang, C.; Li, J.; Chen, K.; Xia, Y.; Li, S.; Xu, L.; Lu, X.; Wang, W.; Guo, C. Fucoidan Protects against Concanavalin A-Induced Acute Liver Injury: Focus on P38 MAPK/NF-kappaB Pathway Activity. *Biol. Targets Ther.* 2018, 12, 1–15. [CrossRef] [PubMed]

113. Li, C.; Gao, Y.; Xing, Y.; Zhu, H.; Shen, J.; Tian, J. Fucoidan, a sulfated polysaccharide from brown algae, against myocardial ischemia-reperfusion injury in rats via regulating the inflammation response. *Food Chem. Toxicol.* 2011, 49, 2090–2095. [CrossRef] [PubMed]

114. Li, J.; Chen, K.; Li, S.; Liu, T.; Wang, F.; Xia, Y.; Lu, J.; Zhou, Y.; Guo, C. Pretreatment with Fucoidan from *Fucus vesiculosus* Protected against ConA-Induced Acute Liver Injury by Inhibiting Both Intrinsic and Extrinsic Apoptosis. *PLoS ONE* 2016, 11, e0152570. [CrossRef] [PubMed]

115. Soin, J.; Kurzejamska, E.; Gaciong, Z.; Henrykowska, G.; Bojakowski, K. Fucoidan Inhibits Vascular Remodeling in Transplant Aneurysm through Interfering the Leukocyte-endothelial Cells Interaction. *Mol. Med. Rep.* 2018, 17, 7089–7096. [CrossRef]

116. Zhou, M.; Ding, Y.; Cai, L.; Wang, Y.; Lin, Z.; Shi, Z. Low molecular weight fucoidan attenuates experimental abdominal aortic aneurysm through interfering the leukocyte-endothelial cells interaction. *Mol. Med. Rep.* 2018, 17, 7089–7096. [CrossRef]

117. Liu, T.; Wang, F.; Xia, Y.; Lu, J.; Zhou, Y.; Guo, C. Pretreatment with Fucoidan from *Fucus vesiculosus* Protected against ConA-Induced Acute Liver Injury by Inhibiting Both Intrinsic and Extrinsic Apoptosis. *PLoS ONE* 2016, 11, e0152570. [CrossRef] [PubMed]

118. Xia, Y.; Lu, J.; Zhou, Y.; Guo, C. Pretreatment with Fucoidan from *Fucus vesiculosus* Protected against ConA-Induced Acute Liver Injury by Inhibiting Both Intrinsic and Extrinsic Apoptosis. *PLoS ONE* 2016, 11, e0152570. [CrossRef] [PubMed]

119. Liu, T.; Wang, F.; Xia, Y.; Lu, J.; Zhou, Y.; Guo, C. Pretreatment with Fucoidan from *Fucus vesiculosus* Protected against ConA-Induced Acute Liver Injury by Inhibiting Both Intrinsic and Extrinsic Apoptosis. *PLoS ONE* 2016, 11, e0152570. [CrossRef] [PubMed]

120. Schulman, I.G. Liver X receptors link lipid metabolism and inflammation. *FEBS Lett.* 2017, 591, 2978–2991. [CrossRef]

121. Gonzalez, N.A.; Castrillo, A. Liver X receptors as regulators of macrophage inflammatory and metabolic pathways. *Biochim. Biophys. Acta.* 2011, 1812, 982–994. [CrossRef]

122. Irfan, M.; Kwon, T.-H.; Yun, B.-S.; Park, N.-H.; Rhee, M.H. Eisenia bicyclus (brown alga) modulates platelet function and inhibits thrombus formation via impaired P2 Y 12 receptor signaling pathway. *Phytotherapy Research* 2018, 40, 79–87. [CrossRef]

123. Han, E.J.; Kim, H.S.; Sanjeewa, K.K.A.; Herath, K.; Jeon, Y.J.; Jee, Y.; Lee, J.; Kim, T.; Shim, S.Y.; Ahn, G. Eckol from *Ecklonia cava* Suppresses Immunoglobulin E-mediated Mast Cell Activation and Passive Cutaneous Anaphylaxis in Mice. *Nutrients* 2020, 12, 1361. [CrossRef] [PubMed]
124. Herath, K.H.I.N.M.; Mihindukulasooriya, S.P.; Kim, H.J.; Kim, A.; Kim, H.J.; Jeon, Y.J.; Lee, Y. Oral administration of polyphenol-rich Sargassum horneri suppresses particulate matter exacer-bated airway inflammation in murine allergic asthma: Relevance to the TLR mediated NF-kappa B pathway inhibition. *J. Funct. Foods* **2020**, *71*, 103991. [CrossRef]

125. Sugiura, Y.; Nagayama, K.; Kinoshita, Y.; Tanaka, R.; Matsushita, T. The anti-allergic effect of the ethyl acetate fraction from an *Ecklonia kurrene* extract. *Food Agric. Immunol.* **2015**, *26*, 181–193. [CrossRef]

126. Son, M.; Oh, S.; Choi, J.; Jang, J.T.; Choi, C.H.; Park, K.Y.; Son, K.H.; Byun, K. Attenuation of Inflammation and Leptin Resistance by Pyrogallol-Phloroglucinol-6,6-Bieckol on in the Brain of Obese Animal Models. *Nutrients* **2019**, *11*, 2773. [CrossRef] [PubMed]

127. Son, M.; Oh, S.; Choi, J.; Jang, J.T.; Choi, C.H.; Park, K.Y.; Son, K.H.; Byun, K. The Phlorotannin-Rich Fraction of *Ecklonia cava* Extract Attenuated the Expressions of the Markers Related with Inflammation and Leptin Resistance in Adipose Tissue. *Int. J. Endocrinol.* **2020**, *2020*, 1–11. [CrossRef]

128. Eo, H.; Jeon, Y.-J.; Lee, M.; Lim, Y. Brown Alga *Ecklonia cava* Polyphenol Extract Ameliorates Hepatic Lipogenesis, Oxidative Stress, and Inflammation by Activation of AMPK and SIRT1 in High-Fat Diet-Induced Obese Mice. *J. Agric. Food Chem.* **2014**, *63*, 349–359. [CrossRef] [PubMed]

129. Yang, Y.-I.; Ahn, J.-H.; Choi, Y.S.; Choi, J.-H. Brown alga phlorotannins enhance the tumoricidal effect of cisplatin and ameliorate cisplatin nephrotoxicity. *Gynecol. Oncol.* **2015**, *136*, 355–364. [CrossRef] [PubMed]

130. Kim, S.; Choi, S.-I.; Kim, G.-H.; IIm, J.-Y. Anti-Inflammatory Effect of *Ecklonia cava* Extract on Porphyromonas gingivalis Lipopolysaccharide-Stimulated Macrophages and a Periodontitis Rat Model. *Nutrients* **2019**, *11*, 1143. [CrossRef]

131. Kim, E.A.; Kim, S.Y.; Ye, B.R.; Kim, J.; Ko, S.C.; Lee, W.W.; Kim, K.N.; Choi, I.W.; Jung, W.K.; Heo, S.J. Anti-inflammatory effect of Apo-γ-fucoxanthinone via inhibition of MAPKs and NF-kB signaling pathway in LPS-stimulated RAW 264.7 macrophages and zebrafish model. *Int. Immunopharmacol.* **2018**, *59*, 339–349. [CrossRef]

132. Kang, K.; Park, Y.; Hwang, H.J.; Kim, S.H.; Shin, H.-C. Antioxidative properties of brown algae polyphenolics and their perspectives as chemopreventive agents in reducing vascular risk factors. *Arch. Pharm. Res.* **2003**, *26*, 286–293. [CrossRef] [PubMed]

133. Kim, S.Y.; Kim, E.A.; Kang, M.C.; Lee, J.H.; Yang, H.W.; Lee, J.S.; Lim, T.I.; Jeon, Y.J. Polyphenol-rich fraction from *Eisenia arborea* Suppress Chemical Mediator Release and Cy-clooxygenase-2 Signaling to Alleviate Mouse Ear Swelling. *Mar. Drugs* **2018**, *16*, 300. [CrossRef]

134. Sugiura, Y.; Usui, M.; Katsuzaki, H.; Imai, K.; Kakinuma, M.; Amano, H.; Miyata, M. Orally Administered Phlorotannins from *Ishige okamurae* (a brown alga) processing by-product reduces LPS-induced inflammation in vitro and in vivo in a zebrafish model. *Algae* **2014**, *29*, 165–174. [CrossRef]

135. Li, S.; Liu, J.; Zhang, M.; Chen, Y.; Zhu, T.; Wang, J. Protective Effect of Eck against Acute Hepatic Injury Induced by Carbon Tetrachloride in Mice. *Mar. Drugs* **2018**, *16*, 267. [CrossRef] [PubMed]

136. Sugiura, Y.; Nagayama, K.; Kinoshita, Y.; Tanaka, R.; Matsushita, T. The anti-allergic effect of the ethyl acetate fraction from an *Ecklonia kurrene* extract. *Food Agric. Immunol.* **2015**, *26*, 181–193. [CrossRef]

137. Choi, J.; Oh, S.; Son, M.; Byun, K. Pyrogallol-Phloroglucinol-6,6-Bieckol Alleviates Obesity and Systemic Inflammation in a Mouse Model by Reducing Expression of RAGE and RAGE Ligands. *Mar. Drugs* **2019**, *17*, 612. [CrossRef] [PubMed]

138. Son, M.; Oh, S.; Lee, H.S.; Chung, D.-M.; Jang, J.T.; Jeon, Y.-J.; Choi, C.H.; Park, K.Y.; Son, K.H.; Byun, K. *Ecklonia cava* Extract Attenuates Endothelial Cell Dysfunction by Modulation of Inflammation and Brown Adipocyte Function in Perivascular Fat Tissue. *Nutrients* **2019**, *11*, 2795. [CrossRef]

139. Goc, A.; Gehring, G.; Baltin, H.; Niedzwiecki, A.; Rath, M. Specific composition of polyphenolic compounds with fatty acids as an approach in helping to reduce spirochete burden in Lyme disease: In vivo and human observational study. *Ther. Adv. Chronic Dis.* **2020**, *11*, [CrossRef]

140. Park, E.Y.; Kim, E.H.; Kim, M.H.; Seo, Y.W.; Lee, J.I.; Jun, H.S. Polyphenol-Rich Fraction of Brown Alga *Ecklonia cava* Collected from Gijang, Korea, Reduces Obesity and Glucose Levels in High-Fat Diet-Induced Obese Mice. *Evid. Based Complement Altern. Med.* **2012**, *2012*, 481921. [CrossRef]

141. Zhao, Z.; Bao, X.Q.; Zhang, Z.; Liu, H.; Zhang, D. Phloroglucinol derivative compound 21 attenuates cuprizone-induced multiple sclerosis mice through pro-moting remyelination and inhibiting neuroinflammation. *Sci. China Life Sci.* **2020**, *63*, 905–914. [CrossRef]

142. Zhao, Z.; Bao, X.Q.; Zhang, Z.; Li, F.; Liu, H.; Zhang, D. Novel phloroglucinol derivative Compound 21 protects experimental autoimmune encephalomyelitis rats via inhibiting Th1/Th17 cell infiltration. *Brain Behav. Immun.* **2020**, *87*, 751–764. [CrossRef]

143. Miyashita, K.; Hosokawa, M. Carotenoids as a Nutraceutical Therapy for Visceral Obesity. In *Nutrition in the Prevention and Treatment of Abdominal Obesity*; Watson, R.R., Ed.; Academic Press: San Diego, CA, USA, 2014; pp. 329–340. [PubMed]

144. Sugawara, T.; Baskaran, V.; Suzuki, W.; Nagao, A. Brown Algae Fucoxanthin Is Hydrolyzed to Fucoxanthinyl during Absorption by Caco-2 Human Intestinal Cells and Mice. *J. Nutr.* **2012**, *132*, 946–951. [CrossRef]

145. Maeda, H.; Kanno, S.; Kodate, M.; Hosokawa, M.; Miyashita, K. Fucoxanthinol, Metabolite of Fucoxanthin, Improves Obesity-Induced Inflammation in Adipocyte Cells, *Mar. Drugs* **2017**, *15*, 4799–4813. [CrossRef] [PubMed]

146. Martin, L.J. Fucoxanthin and Its Metabolite Fucoxanthinol in Cancer Prevention and Treatment. *Mar. Drugs* **2015**, *13*, 4784–4798. [CrossRef]
Menna, M.; Imperatore, C.; D’Aniello, F.; Aiello, A. Meroterpenes from Marine Invertebrates: Structures, Occurrence, and Ecological Implications. *Mar. Drugs* **2013**, *11*, 1602–1643. [CrossRef]

Gwon, W.-G.; Joung, E.-J.; Shin, T.; Usuki, T.; Wakamatsu, N.; Kim, H.-R. Meroterpinoid-rich fraction of the ethanol extract from *Sargassum serratifolium* suppresses TNF-α-induced monocytes adhesion to vascular endothelium and vascular inflammation in high cholesterol-fed C57BL/6j mice. *J. Funct. Foods* **2018**, *46*, 384–393. [CrossRef]

Zhang, H.; Tang, Y.; Zhang, Z.; Zhang, S.; Qu, J.; Wang, X.; Kong, R.; Han, C.; Liu, Z. Fucoxanthin: A Promising Medicinal and Nutritional Ingredient. *Evid. Based Complement. Altern. Med.* **2015**, *2015*, 1–10. [CrossRef]

Kong, Z.-L.; Sudirman, S.; Hsu, Y.-C.; Su, C.-Y.; Kuo, H.-P. Fucoxanthin-Rich Brown Algae Extract Improves Male Reproductive Function on Streptozoto-cin-Nicotinamide-Induced Diabetic Rat Model. *Int. J. Mol. Sci.* **2019**, *20*, 4485. [CrossRef] [PubMed]

Kong, Z.-L.; Kao, N.-J.; Hu, J.-Y.; Wu, C.-S. Fucoxanthin-Rich Brown Algae Extract Decreases Inflammation and Attenuates Collitis in Colon Cancer in Mice. *J. Food Nutr. Res.* **2016**, *4*, 137–147.

Wang, P.-T.; Sudirman, S.; Hsieh, M.-C.; Hu, J.-Y.; Kong, Z.-L. Oral supplementation of fucoxanthin-rich brown algae extract ameliorates cisplatin-induced testicular damage in hamsters. *Biomed. Pharmacother.* **2020**, *125*, 109992. [CrossRef] [PubMed]

Chen, L.; Deng, H.; Cui, H.; Fang, J.; Zuo, Z.; Deng, J.; Li, Y.; Wang, X.; Zhao, L. Inflammatory responses and inflammation-associated diseases in organs. *OncoTargets Ther.* **2017**, *9*, 7204–7218. [CrossRef]

Ayala, A.; Muñoz, M.F.; Argüelles, S. Lipid Peroxidation: Production, Metabolism, and Signaling Mechanisms of Malondialdehyde and 4-Hydroxy-2-Nonenal. *Oxid. Med. Cell. Longev.* **2014**, *2014*, 360438. [CrossRef]

Tan, C.-P.; Hou, Y.-H. First Evidence for the Anti-inflammatory Activity of Fucoxanthin in High-Fat-Diet-Induced Obesity in Mice and the Antioxidant Functions in PC12 Cells. *Inflammation* **2013**, *37*, 443–450. [CrossRef]

Maeda, H.; Hosokawa, M.; Sashima, T.; Murakami-Funayama, K.; Miyashita, K. Anti-obesity and anti-diabetic effects of fucoxanthin on diet-induced obesity conditions in a murine model. *Med. Mol. Rep.* **2009**, *2*, 897–902. [CrossRef] [PubMed]

Sugiura, Y.; Kinoshita, Y.; Usui, M.; Tanaka, R.; Matsushita, T.; Miyata, M. The Suppressive Effect of a Marine Carotenoid, Fucoxanthin, on Mouse Ear Swelling through Regulation of Activities and mRNA Expression of Inflammation-associated Enzymes. *Food Sci. Technol. Res.* **2016**, *22*, 227–234. [CrossRef]

Kwon, M.; Lim, S.-J.; Joung, E.-J.; Lee, B.; Oh, C.-W.; Kim, H.-R. Meroterpenoid-rich fraction of an ethanolic extract from *Sargassum serratifolium* alleviates obesity and non-alcoholic fatty liver disease in high fat-fed C57BL/6j mice. *J. Funct. Foods* **2018**, *47*, 288–298. [CrossRef]

Cheng, I.C.; Weng, S.-Y.; Wu, M.-S.; Suk, F.-M.; Lien, G.-S.; Chen, C.-N. Low-molecular-weight fucoidan and high-stability fucoxanthin decrease serum alanine transaminase in patients with nonalcoholic fatty liver disease—A double-blind, randomized controlled trial. *Adv. Dig. Med.* **2019**, *6*, 116–122. [CrossRef]

Kurylowicz, A.; Jonas, M.; Lisik, W.; Jonas, M.; Wierzbicki, Z.; Chmura, A.; Puzianowska-Kuznicka, M. Obesity is associated with a decrease in expression but not with the hypermethylation of thermogene-sis-related genes in adipose tissues. *J. Transl. Med.* **2015**, *13*, 31. [CrossRef]

Borzuie, S.; Rathgeber, B.M.; Stupart, C.M.; MacIsaac, J.; MacLaren, L.A. Effects of Dietary Inclusion of Seaweed, Heat Stress and Genetic Strain on Performance, Plasma Biochemical and Hematological Parameters in Laying Hens. *Animals* **2020**, *10*, 1570. [CrossRef]

Kawasaki, S.; Horibe, S.; Sasaki, N.; Tanahashi, T.; Mizuno, S.; Hamaguchi, T.; Rikitake, Y. Inhibitory Effects of Sodium Alginate on Hepatic Steatosis in Mice Induced by a Methionine- and Choline-deficient Diet. *Mar. Drugs* **2019**, *17*, 104. [CrossRef] [PubMed]

Lee, H.H.; Cho, Y.J.; Yu, D.; Chung, D.; Kim, G.-H.; Kang, H.; Cho, H. Undaria pinnatifida Fucoidan-Rich Extract Induces Both Innate and Adaptive Immune Responses. *Nat. Prod. Commun.* **2019**, *14*, 1. [CrossRef]

Wang, W.; Lu, J.-B.; Wang, C.-S.; Zhang, H.-H.; Li, C.-Y.; Qian, G.-Y. Effects of *Sargassum fusiforme* polysaccharides on antioxidant activities and intestinal functions in mice. *Int. J. Biol. Macromol.* **2013**, *58*, 127–132. [CrossRef] [PubMed]

Nagamine, T.; Kadona, K.; Tomori, M.; Nakajima, K.; Iha, M. Activation of NK cells in male cancer survivors by fucoidan extracted from *Cladosiphon okamuranus*. *Mol. Clin. Oncol.* **2019**, *12*, 81–88. [CrossRef] [PubMed]

Irhimeh, M.R.; Fitton, J.H.; Lowenthal, R.M. Fucoidan ingestion increases the expression of CXCR4 on human CD34+ cells. *Exp. Hematol.* **2007**, *35*, 989–994. [CrossRef]

Negishi, H.; Mori, M.; Mori, H.; Yamori, Y. Supplementation of Elderly Japanese Men and Women with Fucoidan from Seaweed Increases Immune Responses to Seasonal Influenza Vaccination. *J. Nutr.*** **2013**, *143*, 1794–1798. [CrossRef] [PubMed]

Chen, Y.-C.; Cheng, C.-Y.; Liu, C.-T.; Sue, Y.-M.; Chen, T.-H.; Hsu, Y.-H.; Huang, N.-J.; Chen, C.-H. Combined protective effects of oligo-fucoidan, fucoxanthin, and L-carnitine on the kidneys of chronic kidney disease mice. *Eur. J. Pharmacol.* **2021**, *892*, 173708. [CrossRef] [PubMed]

Yokota, T.; Nomura, K.; Nagashima, M.; Kamimura, N. Fucoidan alleviates high-fat diet-induced dyslipidemia and atherosclerosis in ApoE(−/−) mice deficient in apolipoprotein E expression. *J. Nutr. Biochem.* **2016**, *32*, 46–54. [CrossRef] [PubMed]

Kawashima, T.; Murakami, K.; Nishimura, I.; Nakano, I.; Obata, A. A sulfated polysaccharide, fucoidan, enhances the immunomodulatory effects of lactic acid bacteria. *Int. J. Mol. Med.* **2012**, *29*, 447–453. [CrossRef]

Hwang, E.; Park, S.-Y.; Shin, H.-S.; Lee, D.-G.; Yi, T.H. Effect of oral administration of fucosterol from *Hizikia fusiformis* on DNBC-induced atopic dermatitis in NC/Nga mice. *Food Sci. Biotechnol.* **2014**, *23*, 593–599. [CrossRef]